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A B S T R A C T
Background
Hypothalamic-pituitary-adrenal (HPA) axis dysregulation has been implicated in the development and relapse of psychotic disorders.
Elevated cortisol secretion has been positively linked with symptom severity in people with psychosis. Antiglucocorticoid and related
drugs that target the HPA axis may be useful for the treatment of individuals with psychosis.
Objectives
1. To determine the effects of antiglucocorticoid and related drugs for the treatment of psychosis, when used alone or in combination
with antipsychotic medication.
2. To determine whether the effects of these medications differs between those in a prodromal phase or first episode of psychosis, and
those with more established illness.
Search methods
We searched the Cochrane Schizophrenia Group’s Trials Register (August 2009 and April 2014).
Selection criteria
Randomised controlled trials (RCTs) comparing antiglucocorticoid and related drugs compared to placebo (either as a sole treatment
or as an adjunct to atypical antipsychotics, typical antipsychotics, antidepressants or other combination treatment) for people with a
primary diagnosis of a psychotic disorder, or for individuals at high risk of developing a psychotic disorder.
Data collection and analysis
Review authors independently selected trials, assessed methodological quality and extracted data. We used a fixed-effect meta-analysis.
We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes, and mean differences (MDs) and
standardised mean differences (SMDs) with 95% CIs for continuous measures. We assessed risk of bias for included studies and used
GRADE (Grading of Recommendations Assessment, Development and Evaluation) to create a ’Summary of findings’ table.
1Antiglucocorticoid and related treatments for psychosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
We included 11 studies that randomly assigned 509 people with schizophrenia, schizoaffective disorder or psychotic depression. No
trials were conducted in patients at their first episode of psychotic illness and none included populations at high risk for developing
psychosis. Our pre-stated outcomes of interest were mental state, global state, general functioning, adverse effects and quality of life.
Two trials compared antiglucocorticoid drugs (mifepristone) versus placebo as sole treatment. Limited data from one trial showed no
difference in the proportion responding to mifepristone when mental state was assessed immediately post intervention using the Brief
Psychiatric Rating Scale (BPRS) (n = 5, 1 RCT, MD -5.20, 95% CI -17.91 to 7.51; very low-quality evidence); depressive symptoms
(Hamilton Rating Scale for Depression (HAMD) total) were also similar between groups (n = 5, 1 RCT, MD 1.67, 95% CI -16.44
to 19.78; very low-quality evidence). However, a significant difference favoured treatment at short-term follow-up for global state (30%
reduction in total BPRS, n = 221, 1 RCT, RR 0.58, 95% CI 0.38 to 0.89; low-grade quality evidence). This effect was also seen for
short-term positive psychotic symptoms (50% reduction in BPRS positive symptom subscale, n = 221, 1 RCT, RR 0.60, 95% CI 0.43
to 0.84; low-grade quality evidence). Participants receiving mifepristone experienced a similar overall number of adverse effects as those
receiving placebo (n = 226, 2 RCTs, RR 0.92, 95% CI 0.77 to 1.09; moderate-quality evidence). No data on general functioning or
quality of life were available.
One trial compared an antiglucocorticoid, dehydroepiandrosterone (DHEA), as an adjunct to atypical antipsychotic treatment to
adjunctive placebo. Data for main outcomes of interest were of low quality, and analysis of useable data showed no significant effects
of treatment on mental state or adverse effects. Data on global state, general functioning and quality of life were not available.
Data from six trials comparing antiglucocorticoid drugs as an adjunct to combination treatment versus adjunctive placebo showed no
significant differences between groups in mean endpoint scores for overall psychotic symptoms (n = 171, 6 RCTs, SMD 0.01, 95% CI
- 0.29 to 0.32) or positive psychotic symptoms (n = 151, 5 RCTs, SMD -0.07, 95% CI - 0.40 to 0.25). Data from three trials showed
no differences between groups in mean endpoint scores for negative symptoms (n = 94, 3 RCTs, MD 2.21, 95% CI -0.14 to 4.55).
One study found improvements in global state that were similar between groups (n = 30, 1 RCT, RR 0.58, 95% CI 0.32 to 1.06; very
low-quality evidence). In this comparison, pooled results showed that antiglucorticoids caused a greater overall number of adverse events
(n = 199, 7 RCTs, RR 2.66, 95% CI 1.33 to 5.32; moderate quality evidence), but no quality of life data were available.
Authors’ conclusions
Good evidence is insufficient to conclude whether antiglucocorticoid drugs provide effective treatment for psychosis. Some global
state findings suggest a favourable effect for mifepristone, and a few overall adverse effect findings favour placebo. Additional large
randomised controlled trials are needed to justify findings.
P L A I N L A N G U A G E S U M M A R Y
Antiglucocorticoid and related treatments for psychosis
Psychosis is a broad term that includes several mental illnesses such as schizophrenia, schizophreniform disorder, schizoaffective disorder,
psychotic depression and bipolar disorder with psychotic features. Psychotic disorders affect about 3% of the population and may cause
high levels of disability, making it a significant public health problem both socially and economically.
Stress may result in the release of cortisol and has been linked with both onset and relapse of psychotic disorders. Elevated cortisol levels
have been found in some people with psychosis, especially among those suffering with psychotic depression and those in earlier phases
of psychosis. Antiglucocorticoid drugs have been reported to reduce the effects of cortisol and may be useful for people with psychotic
depression and bipolar disorder. We reviewed all randomised trials comparing antiglucocorticoid and related drugs versus placebo in
people with psychosis - prodromal psychosis or first episode of psychosis.
Eleven studies (involving 509 participants) were included in this review. Several antiglucocorticoid-related drugs were examined,
including dehydroepiandrosterone (DHEA) (n = 5), mifepristone (n = 4), dexamethasone (n = 1) and ketoconazole (n = 1). All
participants were adults with a diagnosis of schizophrenia, schizoaffective disorder or psychotic depression. Most trials examined giving
antiglucocorticoid drugs as an additional part of regular treatment. Available data from these trials revealed no effects for overall psychotic
symptoms, ’positive’ symptoms or ’negative’ symptoms. One large trial comparing mifepristone versus placebo as the sole treatment
revealed a significant difference in the proportion of people responding to treatment with mifepristone versus placebo. This effect was
not seen immediately but 21 days after the intervention was begun. Adverse effect data varied. When individual anticorticoids such as
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mifepristone and DHEA were compared with placebo, the incidence of side effects was similar between groups; however, pooled data
on various antiglucorticoids given as an adjunct to combination treatment showed that antiglucocorticoids increased incidence of side
effects than placebo. In summary, very few trials are under way, and most involve a small number of people. Limited available data do
not provide enough evidence to support the use of antiglucocorticoid treatments for psychosis; additional trials are needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Any antiglucocorticoid compared with placebo as sole treatment (data only for mifepristone) for psychosis
Patient or population: people with psychosis
Settings: inpat ient/ outpat ient
Intervention: any ant iglucocort icoid
Comparison: placebo as sole treatment (data only for m ifepristone)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo as sole treat-
ment (data only for
mifepristone)
Any antiglucocorticoid
M ental state: 1. Gen-
eral - average endpoint
score
BPRS total scores
Follow-up: 4 days
Mean mental state: 1.
General - average end-
point score in interven-
t ion groups was
5.2 lower
(17.91 lower to 7.51
higher)
5
(1 study)
⊕©©©
Very lowa,b,c
M ental state: 2. Spe-
cific - depression - av-
erage endpoint score
HAMD total
Follow-up: 4 days
Mean mental state: 2.
Specif ic - depression -
average endpoint score
in intervent ion groups
was
1.67 higher
(16.44 lower to 19.78
higher)
5
(1 study)
⊕©©©
Very lowa,b,c
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Global state: 1. Gen-
eral - no clinically sig-
nificant improvement -
short term
< 30% improvement on
BPRS
Follow-up: 7 days
Lowd RR 0.58
(0.38 to 0.89)
221
(1 study)
⊕⊕©©
Lowe,f
200 per 1000 116 per 1000
(76 to 178)
M oderated
400 per 1000 232 per 1000
(152 to 356)
Highd
600 per 1000 348 per 1000
(228 to 534)
Global state: 2. Spe-
cific: positive - no clin-
ically significant im-
provement - short term
(< 50%improvement on
BPRS PSS)
Follow-up: 7 days
Lowd RR 0.6
(0.43 to 0.84)
221
(1 study)
⊕⊕©©
Lowe,f
300 per 1000 180 per 1000
(129 to 252)
M oderated
500 per 1000 300 per 1000
(215 to 420)
Highd
700 per 1000 420 per 1000
(301 to 588)
General functioning:
improved to an impor-
tant degree
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome
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Adverse effects: gen-
eral: overall number of
events
Follow-up: 7 days
Lowd RR 0.92
(0.77 to 1.09)
226
(2 studies)
⊕⊕⊕©
M oderatee
500 per 1000 460 per 1000
(385 to 545)
M oderated
700 per 1000 644 per 1000
(539 to 763)
Highd
900 per 1000 828 per 1000
(693 to 981)
Quality of life: im-
proved to an important
degree
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aRisk of bias: rated ’serious’ - unclear how undertaken, groups imbalanced.
bImprecision: rated ’serious’ - small study.
cPublicat ion bias: rated ’strongly suspected’ - one very small t rial, may well be other unpublished work.
dModerate risk roughly equal to that of people in control group of trial.
eRisk of bias: rated ’serious’ - allocat ion concealment unclear, blinding untested, study authors allied with relevant company.
f Indirectness: rated ’serious’ - BPRS not direct measure of global state.
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B A C K G R O U N D
Description of the condition
Psychosis is a generic term that encompasses a group of severe
mental illnesses with considerable variation in prognosis, includ-
ing schizophrenia, schizophreniform disorder, schizoaffective dis-
order, psychotic depression and bipolar disorder with psychotic
features. The lifetime prevalence of psychotic disorders is rela-
tively high at around 3%, with many sufferers having a high level
of disability, making it a significant public health problem both
socially and economically (Altindag 2007; Murray 1997; Perälä
2007). Antipsychotic medications are the primary treatment for
psychosis. The newer atypical antipsychotics are preferable to typ-
ical antipsychotics, as they are associated with fewer extrapyra-
midal symptoms (Kerwin 2004). Atypical antipsychotics are gen-
erally effective in alleviating the ’positive’ symptoms (e.g. hallu-
cinations, delusions) but have only modest effects on ’negative’
(e.g. anhedonia, withdrawal, flat affect) and cognitive symptoms
(Keefe 1999; Leucht 1999). A significant proportion of patients
are treatment resistant, and many do not achieve complete remis-
sion of symptoms. Although fewer extrapyramidal symptoms have
been reported, significant adverse effects are associated with an-
tipsychotic treatment, such as weight gain and diabetes mellitus,
which can lead to increased risk of a range of co-morbid medi-
cal conditions and medication non-compliance (Alvarez-Jimenez
2008; Newcomer 2005).
Description of the intervention
Psychosocial interventions (such as cognitive-behavioural treat-
ment) for psychosis have been associated with reasonable levels
of efficacy (Pilling 2002). Shifting the focus of intervention from
chronic illness to intervention at earlier stages of the illness has
also resulted in better outcomes (Killackey 2007). An increase in
interest has been noted in the delivery of treatments to young peo-
ple at ultra-high risk (UHR) of developing a psychotic disorder,
or with subthreshold symptoms, to reduce the likelihood of this
group transitioning to a full-blown psychotic disorder (McGorry
2002).
The search for more effective and benign treatments for all phases
of psychotic disorders is ongoing. These may involve alternative
medications to atypical antipsychotics, or adjunctive treatments
to augment symptom reduction or alleviate adverse effects. The
search for more benign treatments is considered particularly im-
portant in the treatment of initial episodes of psychosis and for
UHR patients as they are at an early stage of their illness, and
the potential for positive outcomes is therefore greater (McGorry
2006). Many UHR individuals will not go on to have psychosis
with a chronic deteriorating course (Yung 2007); therefore for
these people, the risks associated with taking medications with se-
rious adverse effects may outweigh the benefits.
Antiglucocorticoid and related drugs that target the hypothala-
mic-pituitary-adrenal (HPA) axis are increasingly investigated as
treatment for psychosis, particularly for those at early stages of ill-
ness and/or as adjunctive treatment. Recent clinical trials suggest
that the antiglucocorticoid drug mifepristone may be useful in
the treatment of individuals with psychotic depression and bipolar
disorder (DeBattista 2006; Young 2004).
How the intervention might work
TheHPA axis has been implicated in the development and relapse
ofmajor psychiatric disorders, including psychosis (Phillips 2006).
Several studies have identified abnormalities of HPA axis function
in patients with schizophrenia (Lammers 1995; Sharma 1988),
psychotic depression (Nelson 1997), bipolar disorder (Watson
2004) and first-episode psychosis (Pariante 2004; Ryan 2004), and
in those at prodromal stages of psychosis (Garner 2005;Thompson
2007).
Higher levels of circulating cortisol and impaired regulation of the
HPA axis have been reported, particularly among patients with
psychotic depression and those in the acute phase of psychosis. It
has been suggested thatHPA axis dysfunctionmay cause or exacer-
bate psychotic and depressive symptoms and neuropsychological
dysfunction. Supporting this is the observation that corticosteroid
therapy used for a variety of medical conditions can often induce
symptoms of depression and psychosis, including hallucinations
and delusions, as well as cognitive impairment (Brown 2001). In
addition, Cushing’s syndrome (a condition characterised by hy-
percortisolaemia) is associated with significant cognitive impair-
ment, which improves when cortisol levels have returned to nor-
mal following treatment (Starkman 1999). Atypical antipsychotics
have been shown to suppress HPA axis activity (Cohrs 2006), and
some evidence suggests that normalisation of HPA axis activity
correlates with improvement in clinical symptoms among patients
with schizophrenia (Zhang 2005). As a result, the HPA axis is in-
creasingly viewed as an important therapeutic target in psychosis.
Why it is important to do this review
A large body of evidence suggests that stress and HPA axis func-
tion are important factors in the development of psychosis. Given
the need for more benign treatments, particularly at earlier stages
of psychosis, a review of the efficacy of antiglucocorticoid and re-
lated medications will be useful. These medications are increas-
ingly popular, but given the uncertain efficacy and side effects for
those with psychosis, a systematic review is essential. A Cochrane
systematic review that examined use of antiglucocorticoids for
mood disorders included nine studies (Gallagher 2005), and given
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the increasing number of trials investigating these medications for
psychosis, this review is timely.
O B J E C T I V E S
1. To determine the effects of antiglucocorticoid and related drugs
for the treatment of psychosis, when used alone or in combination
with antipsychotic medication.
2. To determine whether the effects of these medications differs
between those in the prodromal phase or first episode of psychosis
and those with more established illness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials (RCTs). When a trial
was described as ’double-blind’, but it was only implied that the
study was randomised, we included it in a sensitivity analysis. If
we noted no substantive differences within primary outcomes (see
Types of outcome measures) when these ’implied randomisation’
studies were added, we included these in the final analysis. If we
observed a substantive difference, we used only clearly randomised
trials and described results of the sensitivity analysis in the text.
We excluded quasi-randomised studies, such as those in which
investigators allocated by using alternate days of the week.
Types of participants
We included people with a primary diagnosis of a psychotic disor-
der (including schizophrenia, schizophreniformdisorder, schizoaf-
fective disorder, psychotic depression and bipolar disorder with
psychotic features) diagnosed by a clinician using any diagnos-
tic system, those determined to be at ultra-high risk (UHR) for
psychosis and those in the prodromal phase of psychosis. We
included individuals at all stages of psychosis (e.g. prodromal
through chronic psychosis) treated in an inpatient or outpatient
setting with any length of untreated or treated illness of any sever-
ity. We also included those with co-morbidity.
Types of interventions
1. Pharmacological treatments targeting components of the
hypothalamic-pituitary-adrenal (HPA) axis including the
following main categories:
1.1 Glucocorticoid receptor antagonists (e.g. mifepristone);
1.2 Mineralocorticoid receptor antagonists (e.g. spironolactone);
1.3 Glucocorticoid receptor/mineralocorticoid receptor agonists
(e.g. hydrocortisone, dexamethasone);
1.4Corticotrophin-releasing hormone antagonists (e.g. R121919,
ORG 34116); and
1.5 Steroid-synthesis inhibitors (e.g. metyrapone, ketoconazole)
used alone or as adjunctive treatment.
2. Neuroactive steroids considered to have
antiglucocorticoid effects, such as dehydroepiandrosterone
(DHEA)
3. Comparison interventions
3.1 Placebo
3.2 Atypical antipsychotic treatment
3.3 Typical antipsychotic treatment
3.4 Antidepressant treatment
3.5 Other combination treatment (e.g. atypical or typical antipsy-
chotic or both, antidepressant)
Types of outcome measures
We grouped outcomes into immediate (under two weeks), short-
term (two to 12 weeks) and long-term (over 12 weeks).
Primary outcomes
1. Mental state
1.1 Clinically significant change in mental state (as defined by
individual studies)
1.2 Average change in total psychotic symptom scores
1.3 Average endpoint in total psychotic symptom scores
1.4 Average change in positive symptom scores
1.5 Average endpoint in positive symptom scores
1.6 Average change in negative symptom scores
1.7 Average endpoint in negative symptom scores
Secondary outcomes
1. Global state
1.1 Relapse
1.2 Remission rate
1.3 Transition rate or time to onset of psychosis
1.4 Clinically important change in response (as defined by indi-
vidual studies)
1.5 Leaving the study early
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2. Mental state
2.1 Average change in depressive symptom scores
2.2 Average endpoint in depressive symptom scores
2.3 Average change in anxiety symptom scores
2.4 Average endpoint in anxiety symptom scores
3. Cognitive functioning
3.1 Clinically important change in cognitive functioning in any
of the following domains: executive functioning, working mem-
ory, declarative learning and memory, vigilance/attention or psy-
chomotor speed
3.2 Average endpoint in cognitive functioning scores
3.3 Average change in cognitive functioning scores
4. General functioning
4.1 Clinically important change in general functioning
4.2 Average change in general functioning scores
4.3 Average endpoint in general functioning scores
5. Adverse effects
5.1 General adverse effects
5.2 Serious adverse effects
5.3 Extrapyramidal symptoms (EPS)
5.4 Weight gain
6. Quality of life
6.1 Clinically significant change in quality of life (as defined by
individual studies)
6.2 Average change in quality of life scores
6.3 Average endpoint in quality of life scores
’Summary of findings’ table
We used the GRADE (Grading of Recommendations Assess-
ment, Development and Evaluation) approach to interpret
findings (Schünemann 2008) and used the GRADE profiler
(GRADEPRO) to import data from RevMan 5.1 (Review
Manager) to create ’Summary of findings’ tables. These tables pro-
vide outcome-specific information concerning the overall qual-
ity of evidence from each included study in the comparison, the
magnitude of effects of interventions examined and the sum of
available data on all outcomes rated as important to patient care
and decision making. We selected the following main outcomes
for inclusion in the ’Summary of findings’ table.
1. Mental state
2. Global state
3. General functioning
4. Adverse effects
5. Quality of life
Search methods for identification of studies
Electronic searches
1. Cochrane Schizophrenia Group’s Trials Register
The Trials Search Co-ordinator (TSC) searched the Registry of
Trials of theCochrane SchizophreniaGroup (2014 April 28) using
the following phrase:
(*acetoxyandrost* or *aminoglutethimide* or *corticotropin* or
*corticoid* or *dexamethasone* or *etomidate* or *hydrocorti-
sone* or *ketoconazole* or *metyrapone* or *mifepristone* or
*mitot?ne* or *org?34116* or *r?121919* or *ru?486* or *spirono-
lactone* or *steroid* or *dehydroepiandrosterone*):ti,ab in REF-
ERENCE or (*acetoxyandrost* or *aminoglutethimide* or *cor-
ticotropin* or *corticoid* or *dexamethasone* or *etomidate* or
*hydrocortisone* or *ketoconazole* or *metyrapone* or *mifepri-
stone* or *mitot?ne* or *org?34116* or *r?121919* or *ru?486*
or *spironolactone* or *steroid* or *dehydroepiandrosterone*):sin
in STUDY
The Registry of Trials of the Cochrane Schizophrenia Group is
compiled by systematic searches of major resources (including
Allied and Complementary Medicine Database (AMED), BIO-
SIS, Cumulative Index to Nursing and Allied Health Literature
(CINAHL), EMBASE,MEDLINE, PsycINFO,PubMed and reg-
istries of clinical trials) and their monthly updates, handsearches
and searches of grey literature and conference proceedings (see
Group Module). No language, date, document type or publica-
tion status limitations are applied when records are included in
the Register.
For previous searches, see Appendix 1.
Searching other resources
1. Reference lists
We searched reference lists of articles and other reviews retrieved
from the search for relevant studies.
2. Handsearching
We handsearched published abstracts from the following con-
ferences: International Early Psychosis Conference, Birmingham,
October 2006; International Early Psychosis Conference, Vancou-
ver, October 2004; Schizophrenia Research, 13th Biennial Winter
Workshop, Davos, February 2006; and Schizophrenia Bulletin,
10th International Congress on Schizophrenia Research, Savan-
nah, April 2005.
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3. Personal communication
We contacted the authors of included trials to ask about additional
trials, published or unpublished. We noted their responses in the
Characteristics of included studies and Description of studies sec-
tions.
Data collection and analysis
Since the protocol for this review was published, the Cochrane
Schizophrenia Group has updated its template for Methods sec-
tions, and we have updated these sections of the text to reflect this.
For previous text, see also Appendix 2.
Selection of studies
Two review authors (BG, SH or LP) independently inspected the
title and abstract of all articles identified in the searches. When
disagreement occurred, we attempted to resolve this by discussion,
and when doubt remained, we acquired the full article for further
inspection. Once we had obtained the full article, we (BG, LP,
SH, SB) independently decided whether the study met the review
criteria. If we could not resolve disagreement by discussion, we
sought further information and added these trials to the list of
those awaiting assessment.
Data extraction and management
1. Extraction
Four review authors (BG, SH, LP, SB) independently extracted
data from all included studies. When disputes arose, we discussed
and documented decisions made and, if necessary, contacted au-
thors of studies for clarification. For remaining problems, a third
review author (BG, SH, LP) helped clarify issues and documented
decisions made. We extracted data presented only in graphs and
figures when possible, but we include these data only when two
review authors independently reported the same result. We at-
tempted to contact study authors through an open-ended request
to obtain missing information or clarification when necessary. For
multi-centre studies, when possible, we separately extracted data
relevant to each component centre.
2. Management
2.1 Forms
We extracted data onto standard, predesigned, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
• the psychometric properties of the measuring instrument
had been described in a peer-reviewed journal (Marshall 2000);
and
• the measuring instrument had not been written or modified
by one of the trialists for that particular trial.
The ideal measuring instrument should be a self report or a re-
port completed by an independent rater or relative (not the ther-
apist). We realise that often this is not reported clearly, and under
Description of studies, we noted whether this was the case.
2.3 Endpoint versus change data
Both endpoint and change data offer advantages. Change data can
remove a component of between-person variability from the anal-
ysis. On the other hand, calculation of change requires two assess-
ments (baseline and endpoint), which can be difficult to perform
in unstable and difficult to measure conditions such as schizophre-
nia. We have decided to use primarily endpoint data and to use
change data only when the former are not available. We com-
bined endpoint and change data in the analysis if possible, as we
preferred to use mean differences (MDs) rather than standardised
mean differences (SMDs) (Higgins 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes often are not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we aimed to apply the following
standards to data before inclusion.
We entered into the analysis data from studies of at least 200 par-
ticipants, for example, irrespective of the following rules, because
skewed data pose less of a problem in large studies.We also entered
change data, as when continuous data are presented on a scale that
includes a possibility of negative values (such as change data), it is
difficult to tell whether data are skewed.We presented and entered
change data into the statistical analyses.
For endpoint data:
1. When a scale started from the nite number zero, we
subtracted the lowest possible value from the mean, and divided
this by the standard deviation. Values lower than 1 strongly
suggest a skew, and we excluded these data. If this ratio was
higher than one but lower than two, skew was suggested. We
entered the data and tested whether inclusion or exclusion of
data changed the results substantially. Finally, if the ratio was
larger than two, we included these data because skew was less
likely (Altman 1996; Higgins 2011).
2. When a scale started from a positive value (such as the
Positive and Negative Syndrome Scale (PANSS); Kay 1986),
which can provide values from 30 to 210, we modified the
calculation described above to take the scale starting point into
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account. In these cases, skew was present if 2 standard deviations
(SD) > (S - S min), where ’S’ was the mean score and ’S min’ was
the minimum score.
2.5 Common measure
To facilitate comparison between trials, we intended, if possible,
to convert variables that can be reported in different metrics, such
as days in hospital (mean days per year, per week or per month),
to a common metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
When possible, we made efforts to convert outcome measures to
dichotomous data, which can be done by identifying cut-off points
on rating scales and dividing participants accordingly into ’clini-
cally improved’ and ’not clinically improved’. It was generally as-
sumed that a 50% reduction in a scale-derived score such as the
Brief Psychiatric Rating Scale (BPRS; Overall 1962) or the Posi-
tive and Negative Syndrome Scale (PANSS; Kay 1986) could be
considered a clinically significant response (Leucht 2005; Leucht
2005a). If data based on these thresholds were not available, we
used the primary cut-off presented by the original study authors.
2.7 Direction of graphs
When possible, we entered data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
antiglucocorticoids. When keeping to this makes it impossible to
avoid outcome titles with clumsy double-negatives (e.g. ’Not un-
improved’), we reported data when the left of the line indicates an
unfavourable outcome. This is noted in the relevant graphs.
Assessment of risk of bias in included studies
Again review authors BG, SH, LP and SB worked independently
to assess risk of bias by using criteria described in the Cochrane
Handbook for Systemic Reviews of Interventions (Higgins 2011) to
assess trial quality. This set of criteria is based on evidence of
associations between overestimation of effect and high risk of bias
of the study, such as sequence generation, allocation concealment,
blinding, incomplete outcome data and selective reporting.
If the two raters disagreed, we determined the final rating by con-
sensus, with involvement of another member of the review group
(BG, LP, SH or SB). When inadequate details of randomisation
and other characteristics of trials were provided, we contacted
study authors to obtain further information. We reported non-
concurrence in quality assessment, but if disputes arose as to which
category a trial was to be allocated, again, we resolved this matter
by discussion.
We noted the level of risk of bias in both the text of the review
and the ’Summary of findings’ table.
Measures of treatment effect
1. Binary data
For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RRs are more intuitive (Boissel 1999) than odds ra-
tios, and that odds ratios tend to be interpreted as RRs by clini-
cians (Deeks 2000). The number needed to treat for an additional
harmful outcome (NNTH) statistic with its confidence intervals
is intuitively attractive to clinicians but is problematic both in
its accurate calculation in meta-analyses and in its interpretation
(Hutton 2009). For binary data presented in the ’Summary of
findings’ table/s, when possible, we calculated illustrative compar-
ative risks.
2. Continuous data
For continuous outcomes, we estimated mean differences (MDs)
and 95% CIs between groups. When different measurement tools
were used tomeasure the same outcome,we estimated standardised
mean differences (SMDs) and 95% CIs between groups.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster-randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data pose problems. First, study authors often fail to ac-
count for intraclass correlation in clustered studies, leading to a
’unit of analysis’ error (Divine 1992) whereby P values are spuri-
ously low, confidence intervals unduly narrow and statistical sig-
nificance overestimated. This causes type I errors (Bland 1997;
Gulliford 1999).
We included no cluster trials in this review. If we had identified
such studies, wewould have applied the following approach:When
clustering was not accounted for in primary studies, we would
present data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. We would seek to contact
first authors of studies to obtain intraclass correlation coefficients
and to ask for clustered data; we would adjust for these by using
accepted methods (Gulliford 1999). When clustering had been
incorporated into the analysis of primary studies, we would have
presented these data as if obtained from a non-cluster-randomised
study but with adjustment for the clustering effect.
We sought statistical advice and have been advised that binary data
as presented in a report should be divided by a ’design effect’. This
is calculated by using the mean number of participants per cluster
(m) and the intraclass correlation coefficient (ICC) [Design effect
= 1 + (m - 1) * ICC] (Donner 2002). If the ICC was not reported,
it was assumed to be 0.1 (Ukoumunne 1999).
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If cluster studies had been appropriately analysed with ICCs con-
sidered and relevant data documented in the report, synthesis with
other studies would be possible using the generic inverse variance
technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect, which
occurs when an effect (e.g. pharmacological, physiological, psy-
chological) of treatment in the first phase is carried over to the
second phase. As a consequence of entry into the second phase,
participants can differ systematically from their initial state despite
a wash-out phase. For the same reason, cross-over trials are not
appropriate when the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
used data only from the first phase of cross-over studies.
3. Studies with multiple treatment groups
When a study had involved more than two treatment arms, if
relevant, we would have presented additional treatment arms in
comparisons. If data had been binary, we would have simply added
these and combined themwithin the two-by-two table. If data had
been continuous, we would have combined data by applying the
formula provided in Section 7.7.3.8 (Combining groups) of the
Cochrane Handbook for Systemic Reviews of Interventions (Higgins
2011). When additional treatment arms were not relevant, we
would not have used these data. One trial in this review included
multiple (four) treatment arms, of which two were irrelevant.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we would not reproduce
these data and would not use them within analyses. If, however,
more than 50% of those in one arm of a study were lost, but
the total loss was less than 50%, we addressed this within the
’Summary of findings’ table/s by downgrading quality. Finally,
we also downgraded quality within ’Summary of findings’ table/s
when total loss was 25% to 50%.
2. Binary
When attrition for a binary outcome was between 0 and 50%,
and when these data were not clearly described, we presented data
on a ’once-randomised-always-analyse’ basis (an intention-to-treat
(ITT) analysis). We assumed that all those leaving the study early
had the same rates of negative outcome as those who completed
the study, with the exception of the outcomes of death and adverse
effects (for these outcomes, we used the rate of those who stayed
in the study - in that particular arm of the trial - for those who
did not). We undertook a sensitivity analysis by testing how prone
primary outcomes were to change when data only from people
who completed the study to that point were compared with the
ITT analysis under the above assumptions.
3. Continuous
3.1 Attrition
When attrition for a continuous outcomewas between 0 and 50%,
and when data only from people who completed the study to that
point were reported, we reproduced these.
3.2 Standard deviations
If standard deviations (SDs) were not reported, we first tried to ob-
tain missing values from study authors. If these were not available,
when measures of variance for continuous data were missing, but
an exact standard error and confidence intervals were available for
group means, and P value or ’t’ value was available for differences
in means, we could calculate SDs by following the rules provided
in the Cochrane Handbook for Systemic Reviews of Interventions
(Higgins 2011): When only the standard error (SE) was reported,
we calculated SDs by using the formula: SD = SE * square root (n).
Chapters 7.7.3 and 16.1.3 of the Cochrane Handbook for Systemic
Reviews of Interventions (Higgins 2011) presents detailed formulae
for estimating SDs from P values, t or F values, confidence in-
tervals, ranges or other statistics. If these formulae did not apply,
we calculated SDs according to a validated imputation method
based on the SDs of the other included studies (Furukawa 2006).
Although some of these imputation strategies can introduce error,
the alternative would be to exclude outcomes of a given study and
thus to lose information. We nevertheless examined the validity of
the imputations by performing a sensitivity analysis that excluded
imputed values.
3.3 Assumptions about participants who left trials early or
were lost to follow-up
Variousmethods are available to account for participants who leave
trials early or are lost to follow-up. Some trials present only the re-
sults of study completers, others use themethod of last observation
carried forward (LOCF) andmore recently investigators have used
methods such as multiple imputation or mixed-effects models for
repeated measurements (MMRM) as the standard. Although the
latter methods seem somewhat better than LOCF (Leon 2006),
we believe that the high percentage of participants leaving studies
early and differences between groups in reasons for leaving studies
early often represent the core problem in randomised schizophre-
nia trials. Therefore we did not exclude studies on the basis of
the statistical approach used. However, we preferred to use data
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from studies based on more sophisticated approaches. For exam-
ple, we preferred MMRM or multiple imputation to LOCF, and
we presented completer analyses only if no ITT data were avail-
able. Moreover, we addressed this issue in the item “Incomplete
outcome data” for the risk of bias tool.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without knowledge
of comparison data, to judge clinical heterogeneity. We simply
inspected all studies for clearly outlyingpeople or situations thatwe
had not predictedwould arise.When such situations or participant
groups arose, we fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without knowledge
of comparison data, to judge methodological heterogeneity. We
simply inspected all studies for clearly outlying methods that we
had not predictedwould arise.When suchmethodological outliers
arose, we fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the I
2 method alongside theChi2 P value. I2 provides an estimate of the
percentage of inconsistency thought to be due to chance (Higgins
2003). The importance of the observed value of I2 depends on
both magnitude and direction of effects and strength of evidence
for heterogeneity (e.g. P value from Chi2 test, confidence interval
for I2). An I2 estimate greater than or equal to around 50% accom-
panied by a statistically significant Chi2 statistic was interpreted
as evidence of substantial levels of heterogeneity (Section 9.5.2 -
Higgins 2011).When we found substantial levels of heterogeneity
in the primary outcome, we explored reasons for heterogeneity
(Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when dissemination of research findings is
influenced by the nature and direction of results. These are de-
scribed in Section 10.1 of the Cochrane Handbook for Systemic
Reviews of Interventions (Higgins 2011). We attempted to locate
protocols of included randomised trials. If the protocol was avail-
able, we compared outcomes in the protocol versus those in the
published report. If the protocol was not available, we compared
outcomes listed in the Methods section of the trial report versus
actually reported results.
2. Funnel plot
Reporting biases arise when dissemination of research findings is
influenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook for
Systemic Reviews of Interventions (Higgins 2011).We are aware that
funnel plotsmay be useful for investigating reporting biases but are
of limited power for detecting small-study effects. We did not use
funnel plots for outcomes when we identified 10 or fewer studies,
or when all studies were of similar size. In other cases, when use
of funnel plots is possible, we will seek statistical advice in their
interpretation.
Data synthesis
We understand that no closed argument can be presented for
preference for use of fixed-effect or random-effects models. The
random-effects method incorporates an assumption that different
studies are estimating different, yet related, intervention effects.
This often seems to be true, and the random-effects model takes
into account differences between studies even when no statisti-
cally significant heterogeneity is observed. However, the random-
effects model does present a disadvantage. It puts added weight
onto small studies, which often are themost biased ones. Depend-
ing on the direction of effect, these studies can inflate or deflate
effect size. We chose a fixed-effect model for all analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
• Diagnosis
• ’Prodrome’ versus ’first-onset’ versus ’chronic’
• Type of antiglucocorticoid drug
• Adults versus adolescents
• Length of untreated illness
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1.2 Clinical state, stage or problem
We also proposed to undertake this review to provide an overview
of the effects of antiglucocortoicoids for people with schizophre-
nia in general. In addition, however, we tried to report data on
subgroups of people in the same clinical state or stage and with
similar problems.
2. Investigation of heterogeneity
If inconsistency was high, this was reported. First, we investigated
whether data had been entered correctly. Second, if data were cor-
rect, we visually inspected the graph and successively removed
studies outside of the rest to see whether homogeneity was re-
stored. For this review, we decided that should this occur when
data contributed no more than around 10% of total weighting to
the ’Summary of findings’, we would present the data. If this was
not the case, we would have pooled data and would have discussed
issues. We know of no supporting research for this 10% cut-off,
but we are investigating the use of prediction intervals as an alter-
native to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity was
obvious, we simply stated hypotheses regarding these for future
reviews or other versions of this review. We did not undertake
analyses of this kind.
Sensitivity analysis
We performed sensitivity analyses to investigate the degree to
which effect sizes depended on assumptions made by review au-
thors. Towards this end, we excluded trials with ’high risk’ or ’un-
clear risk’ for allocation concealment, trials with ’high risk’ or ’un-
clear risk’ for blinding of outcome assessment and trials with ’high
risk’ or ’unclear risk’ for ITT analysis.
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if in some way
the study report implied randomisation. For primary outcomes,
we included these studies, and if we observed no substantive dif-
ferences when implied randomised studies were added to those
with better descriptions of randomisation, we included all data
from these studies.
2. Assumptions for lost binary data
When assumptions had to bemade regarding people lost to follow-
up (see Dealing with missing data), we compared the findings of
primary outcomes when we used our assumption/s, and when we
used only data from people who had completed the study to that
point. If we noted a substantial difference, we reported results and
discussed them but continued to employ our assumption.
When assumptions had to bemade regarding missing SDdata (see
Dealing with missing data), we compared the findings of primary
outcomes whenwe used our assumption/s, and whenwe used only
data from people who had completed the study to that point. We
undertook a sensitivity analysis to test how prone results were to
change when completer-only data were compared with imputed
data on the basis of the above assumption. If we noted a substantial
difference, we reported results and discussed them but continued
to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials judged to be at high risk
of bias across one or more of the domains of randomisation (im-
plied as randomised with no additional details available), alloca-
tion concealment, blinding and outcome reporting for the meta-
analysis of the primary outcome. If exclusion of trials at high risk
of bias did not substantially alter the direction of effect or the pre-
cision of effect estimates, we would have included in the analysis
data from these trials.
4. Imputed values
We also undertook a sensitivity analysis to assess the effects of
including data from trials for which we used imputed values for
ICC in calculating the design effect in cluster-randomised trials.
If we noted substantial differences in the direction or precision of
effect estimates in any of the sensitivity analyses listed above, we
did not pool data from excluded trials with those of other trials
contributing to the outcome but presented them separately.
5. Fixed-effect and random-effects
We synthesised all data using a fixed-effect model; however, we
also synthesised data for the primary outcome using a random-
effects model to evaluate whether this approach would alter the
significance of the results.
R E S U L T S
Description of studies
For substantive descriptions of studies, please see Characteristics
of included studies and Characteristics of excluded studies.
Results of the search
In total, we identified 1847 publications through the electronic
search strategy. We judged most of these (1785) to be irrelevant
on the basis of information provided in the title and the abstract,
leaving 62 reports of studies for possible inclusion in the review.
After obtaining full publications of these studies, we excluded 25
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additional publications (see Characteristics of excluded studies ta-
bles). Of the remaining 37 publications, nine are awaiting assess-
ment. The remaining 28 publications described a total of 13 trials,
which met the criteria for inclusion in the review. We classified
two of these trials as ongoing, leaving 11 trials for analysis (Figure
1).
15Antiglucocorticoid and related treatments for psychosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram 2009, 2014 searches.
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Included studies
1. Setting
Five trials (Belanoff 2001; Nachshoni 2005; Newcomer 1998;
Strous 2003; Strous 2007) were conducted in an inpatient setting,
three trials (DeBattista 2006; Flores 2006; Ritsner 2006) consisted
of both inpatients and outpatients and the remaining three trials
(Gallagher 2005; Marco 2002; Ritsner 2010) took place in an
outpatient setting.
2. Participants
All trials were conducted in an adult population. The youngest
participant was 18 years of age and the oldest was 74 years.
Nine trials (DeBattista 2006; Flores 2006; Gallagher 2005;Marco
2002; Nachshoni 2005; Ritsner 2006; Ritsner 2010; Strous 2003;
Strous 2007) used the Structured Clinical Interview forDSMDis-
orders (SCID) to determine the diagnosis. In Belanoff 2001 and
Newcomer 1998, diagnoses were determined by clinician inter-
view(s).
Eight trials required a diagnosis of schizophrenia or schizoaf-
fective disorder based on the Diagnostic and Statistical Manual
(DSM) III-R (Marco 2002; Newcomer 1998) or IV (Gallagher
2005; Nachshoni 2005; Ritsner 2006; Ritsner 2010; Strous 2003;
Strous 2007). Four of these trials (Strous 2003; Strous 2007;
Ritsner 2006; Ritsner 2010) consisted of participants with chronic
schizophrenia/schizoaffective disorder of at least two years’ dura-
tion. In addition, Strous 2003 required participants to score 25
or higher on the Scale for the Assessment of Negative Symptoms
(SANS) for inclusion in the trial. Marco 2002 and Gallagher 2005
required patients to be clinically stable but symptomatic (dura-
tion of illness not stated). In the trial by Nachshoni 2005, hospi-
talised patients with schizophrenia with any form of extrapyrami-
dal symptoms (EPS) were referred for study recruitment (duration
of illness not stated).
Three trials included participants with a diagnosis of psychotic
major depression based on DSM IV (Belanoff 2001; DeBattista
2006; Flores 2006).DeBattista 2006 required participants to score
38or higher on theBPRS and20or higher on theHamiltonRating
Scale for Depression (HAMD); Flores 2006 required participants
to score five or higher on the BPRS four-item positive symptom
subscale and 21 or higher on the HAMD (21-item) for inclusion
in the trial.
3. Size
We included 11 trials involving 509 participants (Belanoff 2001;
DeBattista 2006; Flores 2006; Gallagher 2005; Marco 2002;
Nachshoni 2005; Newcomer 1998; Ritsner 2006; Ritsner 2010;
Strous 2003; Strous 2007). Three trials (Belanoff 2001; Gallagher
2005; Ritsner 2006) were of a cross-over design. We used in the
analysis only data from the first intervention phase of the cross-
over trial. The trial by Ritsner 2010 involved multiple treatment
arms; we used in the analysis only data from DHEA and placebo
treatment arms. Sample size varied widely between studies, rang-
ing from five to 221 participants.
4. Interventions
All trials except for two (Belanoff 2001; DeBattista 2006) admin-
istered the intervention treatment as an adjunct to antipsychotic or
regular treatment. In the case of Strous 2007, antipsychotic treat-
ment consisted of stable doses of olanzapine only. In Newcomer
1998, participants received ongoing typical antipsychotic treat-
ment, but anticholinergics were also administered. For all other
trials, regular treatment involved a combination of atypical, typi-
cal and/or antidepressant or other psychotropic medication.
Four trials administered mifepristone (Belanoff 2001; DeBattista
2006; Flores 2006; Gallagher 2005) at a dose of 600 mg/d for
between four and eight days. Five trials administered DHEA
(Nachshoni 2005; Ritsner 2006; Ritsner 2010; Strous 2003;
Strous 2007); doses ranged from 100 mg/d to 400 mg/d, and the
intervention duration ranged from seven days to 12 weeks (see
Characteristics of included studies for details). Ritsner 2010 in-
cluded four treatment arms (pregnenolone - 30 mg, pregnenolone
- 200 mg, DHEA - 400 mg and placebo) and reported only data
from DHEA and placebo arms. One trial (Newcomer 1998) ad-
ministered successive doses (0.5, 1, 1, 1 mg) of dexamethasone
over four days. Another trial (Marco 2002) administered keto-
conazole titrated up to 800 mg/d over four weeks.
5. Outcomes
5.1 Assessment times
All trials conducted baseline and post-treatment assessments (i.e.
immediately following cessation of the intervention). Three trials
(DeBattista 2006; Gallagher 2005; Newcomer 1998) conducted
follow-up assessments up to a maximum of 21 days following the
end of the intervention.
5.2 Missing outcomes
None of the trials examined relapse or remission rates. No trials in-
volved first-episode psychosis patients or individuals at ultra-high
risk for psychosis; therefore we did not examine time to transition
to psychosis or transition rates.
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5.3 Outcome scales
5.3.1 Mental state
5.3.1.1 Brief Psychopathological Rating Scale - BPRS (Overall
1962)
This observer-rated scale is used to assess the severity of a range of
psychiatric symptoms, including psychotic symptoms. Items are
rated from zero (absent) to six (severe) according to clearly de-
fined anchor points. Scores can range from 0 to 126, with high
scores indicating more severe symptoms. The BPRS has displayed
good concurrent and discriminant validity in studies involving
psychotic participants (Faustman 1994) and high inter-rater reli-
ability ranging from 0.67 to 0.88 for individual items and overall
score (Hedlund 1980). The BPRS positive symptom subscale (as
defined by studies included in this review) consists of the follow-
ing four core psychotic items of the BPRS: suspiciousness, hal-
lucinatory behaviour, disorganised thinking and unusual thought
content.
5.3.1.2 Positive andNegative SymptomScale - PANSS (Kay1986)
This observer-rated scale is used to evaluate positive, negative and
other symptom dimensions in schizophrenia. This scale consists
of 30 items, each of which can be defined on a seven-point scoring
system ranging fromone (absent) to seven (extreme). This scale can
be divided into three subscales formeasuring the severity of general
psychopathology (PANSS-G), positive symptoms (PANSS-P) and
negative symptoms (PANSS-N).
5.3.1.3 Scale for Assessment of Negative Symptoms (SANS) (
Andreasen 1989)
This observer-rated scale is widely used to assess negative symp-
toms in psychotic illness. It includes 25 items that collapse to five
subscales: affective flattening, alogia, avolition-apathy, anhedonia-
asociality and attention. All items are rated from zero to five (ab-
sent to severe).
5.3.2.1 Global state
5.3.2.1.1 Response rates
Two trials (DeBattista 2006; Flores 2006) used one or more of the
following measures of efficacy based on BPRS or HAMD scale
level of response: (1) 30% reduction in total BPRS score, (2) 50%
reduction in BPRS positive symptoms subscale (four items of the
BPRS); or (3) 50% reduction in HAMD.
5.3.2.2.2 Hamilton Rating Scale for Depression (HAMD) (
Hamilton 1960) and Anxiety (HAMA) (Hamilton 1959)
The HAMD is an observer-rated scale that is used to assess the
presence and severity of depressive states. This scale has 17-item
and 21-item versions and is widely used for clinical assessment
of depressive symptoms. The HAMA is widely used to assess the
severity of anxiety symptoms. It consists of 14 items, each defined
by a series of symptoms.
5.3.2.2.3 Calgary Depression Scale for Schizophrenia - CDSS (
Addington 1997)
This observer-rated scale was specifically developed for assessment
of the level of depression in schizophrenia. The scale is designed to
assess the presence of depression separate from other dimensions
of psychopathology in schizophrenia such as negative symptoms.
5.3.2.3 Cognitive functioning
Seven trials assessed neurocognitive functioning across several do-
mains using a range of cognitive tests. Three trials (Gallagher 2005;
Ritsner 2006; Ritsner 2010) used the Cambridge Neuropsycho-
logical Test Automated Battery (CANTAB). Available data were
insufficient for meta-analysis. We have presented data from only
one trial.
5.3.2.4 General functioning
5.3.2.4.1 Global Assessment of Functioning - GAF (American
Psychiatric Association 2000)
TheGAF is a numerical observer-rated scale (0 to 100) that is used
to assess social, occupational and psychological functioning.
5.3.2.5 Adverse effects
5.3.2.5.1 Extrapyramidal Symptoms Rating Scale - ESRS (
Chouinard 1980)
This observer-rated scale assesses parkinsonian symptoms, dyski-
netic movements and tardive dyskinesia. High scores indicate se-
vere levels of movement disorder.
5.3.2.5.2 The St. Hans Rating Scale - SHRS (Gerlach 1993)
This multi-dimensional observer-rated scale is used to evaluate
neuroleptic-induced hyperkinesia, parkinsonism, akathisia and
dystonia.
5.3.2.5.3 Abnormal Involuntary Movement Scale - AIMS (Guy
1976)
This observer-rated scale is used to assess abnormal involuntary
movements associated with antipsychotic drugs, such as tardive
dyskinesia and chronic akathisia. Scoring consists of rating move-
ment severity in anatomical areas (facial/oral, extremities and
trunk) on a five-point scale (zero to four). A low score indicates
low levels of dyskinetic movement.
5.3.2.5.4 Barnes Akathisia Rating Scale - BARS (Barnes 1989)
This four-item observer-rated scale is used to assess the presence
and severity of drug-induced akathisia. It is the most widely used
comprehensive rating scale for akathisia and includes both objec-
tive items (e.g. observed restlessness) and subjective items (e.g. pa-
tient’s awareness of restlessness and related distress), together with
a global clinical assessment of akathisia.
5.3.2.5.5 Simpson and Angus Scale - SAS (Simpson 1970)
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This observer-rated scale is used to evaluate the presence and sever-
ity of drug-induced parkinsonian symptoms. It is a 10-item rating
scale, and each item is rated on a five-point scale from zero (com-
plete absence of the condition) to four (extreme presence of the
condition).
5.3.2.5.6 Weight gain
Only one trial (Strous 2007) reported average pretreatment and
post-treatment patientweight. Itwas not possible to analyseweight
gain.
5.3.2.6 Quality of life
5.3.2.4.1 Observer-rated Quality of Life scale (QOL) (Heinrichs
1984)
5.3.2.4.2 The Social and Occupational Functioning Assessment
Scale (SOFAS) (American Psychiatric Association 2000)
This numerical observer-rated scale (0 to 100) is used to assess
social and occupational functioning.
Excluded studies
We excluded 25 reports of studies; 12 (Barkai 1985; Brambilla
1988; Katz 2002; Kim 1960; Kline 1968; Korsgaard 1981;
Lembke 2013; Rees 1951; Rees 1956; Rothschild 2005;
Schatzberg 2003; Simpson 2005) were not randomised, eight
(Beasley 1998; David 1999; Iager 1986; Lane 2001; Loranger
1968; Miodownik 2011; Stein 1984; Tollefson 1998) did not in-
volve an antiglucocorticoid or related treatment, two were not in-
tervention studies (Harrigan 2004; Nihalani 2007), one did not
involve patients with a psychotic disorder (Young 2004), one was
not placebo controlled (Belanoff 2002) and one reported no data
that could be included (Silbergeld 1973). Details can be found in
the Characteristics of excluded studies tables.
Ongoing studies
Two trials (Jarskog 2009; Solvason 2008) were described as on-
going trials. We identified no subsequent publications from these
trials in our search.
Studies awaiting assessment
Nine publications (Hardwick 1957; Kleiser 1984; Owen 1996;
Pivac 2002; Sluchevskii 1986; Smidt 1988; Volk 1976; Volk 1977;
Watson 2002 (N0573099798)) are awaiting assessment, as we
were unable to obtain full details on them. One of these publica-
tions (Smidt 1988) is a description of a study registered with Clin-
icalTrials.gov in 2002, but no published reports have followed.
Risk of bias in included studies
For a summary of risk of bias across all trials, see Figure 2 and
Figure 3.
Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All included trials were stated to be randomised. Seven trials
(Gallagher 2005; Marco 2002; Nachshoni 2005; Ritsner 2006;
Ritsner 2010; Strous 2003; Strous 2007) used a computer-gener-
ated randomisation list or random number generation. These tri-
als confirmed that allocation was concealed by a key-based numer-
ical code on envelopes (Marco 2002) or by an independent phar-
macist (Gallagher 2005; Ritsner 2006; Ritsner 2010), or it was
maintained under lock and key in a concealed fashion (Nachshoni
2005; Strous 2003; Strous 2007). These trials were rated as ’low
risk’. Three trials (DeBattista 2006; Flores 2006;Newcomer 1998)
provided no details of randomisation generation nor concealment
of allocation and were rated as ’unclear risk’. The remaining trial
(Belanoff 2001) likewise providednodetails of randomisation gen-
eration nor concealment of allocation and reported an imbalance
in length of illness between groups, which calls into question the
success of randomisation. This trial was rated ’high risk’.
Blinding
All included trials were described as ’double-blind’. When it was
unclear whether the term ’double-blind’ referred to participants,
providers and/or outcome assessors, we sought additional informa-
tion from the study authors. Eight trials (Flores 2006; Gallagher
2005;Marco 2002; Nachshoni 2005; Ritsner 2006; Ritsner 2010;
Strous 2003; Strous 2007) confirmed that participants, providers
and outcome assessors were blind to the treatment condition.
Incomplete outcome data
Three trials reported no participants leaving the study early
(Belanoff 2001; Gallagher 2005; Marco 2002). DeBattista 2006
performed efficacy analyses on the ITT sample (n = 221), which
consisted of all randomly assigned participants who received at
least one dose of study medication. Data were observed at day 28
for 170 of the 221 participants (77%). For the 51 participants with
missing data at day 7 or day 28, BPRS and HAMD data were im-
puted by using a mixed-effects model for repeated measurements.
In Nachshoni 2005, of the 34 randomly assigned participants,
four were withdrawn for failing to meet trial requirements because
investigators altered medication dose during the study and con-
ducted the analysis on 30 participants. In Flores 2006, one par-
ticipant dropped out during the intervention and researchers con-
ducted an observed case analysis. Ritsner 2006 randomly assigned
62 participants. Seven participants failed to complete the 12 weeks
of the cross-over randomisationphase because theywithdrew study
consent after randomisation but had previously received the first
dose of study medication. Investigators conducted an analysis that
included 55 participants. Strous 2003 randomly assigned 30 par-
ticipants. Investigators eliminated three participants from study
analysis after they failed to complete three weeks of the randomisa-
tion phase (selected a priori). They imputed missing data on four
participants by using last observation carried forward (LOCF) (i.e.
analysis was conducted on 27 participants). In Strous 2007, nine
participants dropped out during the intervention and researchers
conducted an ITT analysis. In Newcomer 1998, analyses excluded
participants with missing data (n = 3); however, investigators also
ran analyses that included all participants (n = 19) by applying
conservative adjustments for missing data. Ritsner 2010 randomly
assigned 58 participants to one of four treatment groups (preg-
nenolone - 30 mg, pregnenolone - 200 mg, DHEA - 400 mg and
placebo). Fourteen participants left the study early after complet-
ing at least four weeks of the trial. Investigators conducted analyses
on 44 participants, allocated 16 to placebo (five of whom left the
study early) and allocated 16 to DHEA (three of whom left the
study early). They conducted analyses on 11 participants in the
placebo group and in 13 in the DHEA group.
Selective reporting
Most trials reported all outcome measures. Belanoff 2001 did not
report data from the Clinical Global Impression (CGI) scale and
paragraph recall test. Marco 2002 stated that they found no sig-
nificant differences, but investigators provided no data for the fol-
lowing outcome measures; PANSS, Beck Depression Inventory
(BDI), Bunney-Hamburg Global Rating Scale and neurocogni-
tive tests. In the trial by Nachshoni 2005, which investigated ef-
fects of DHEA administration on medication-induced EPS, the
frequency of participants demonstrating tardive dyskinesia (10%)
or dystonia (0%) was very low; therefore, researchers could not
analyse these measures. Finally, Newcomer 1998 did not report
symptomatic outcomes (e.g. BPRS/PANSS, SANS).
Other potential sources of bias
Other potential sources of bias included the small sample size
in some trials (e.g. Belanoff 2001, n = 5). Baseline imbalances
in gender (Marco 2002; Strous 2003), length of illness (Belanoff
2002) and symptom severity (Strous 2007) were evident between
groups. In Marco 2002, participants receiving ketoconazole had
higher baseline cortisol levels and appeared to be taking a greater
number of concomitant medications, suggesting that they may
have had a more severe or complex disorder. Some study authors
in DeBattista 2006 were employed by or received funding from
the sponsor, and in Flores 2006, one study author had a financial
interest in the company that licensed IP (Intellectual Property)
for use of mifepristone in the treatment of patients with psychotic
depression.
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Effects of interventions
See: Summary of findings for the main comparison Any
antiglucocorticoid compared with placebo as sole treatment (data
only for mifepristone) for psychosis; Summary of findings 2 Any
antiglucocorticoid compared with placebo as adjunct to atypical
antipsychotic treatment (data only for DHEA) for psychosis;
Summary of findings 3 Any antiglucocorticoid compared with
placebo as adjunct to combination treatment for psychosis
1. Any antiglucocorticoid vs placebo as sole
treatment (data only for mifepristone)
Only Belanoff 2001 andDeBattista 2006, both providingmifepri-
stone treatment, could be included in this comparison (total n =
226).
1.1 Mental state
1.1.1 General: average endpoint score (BPRS total scores,
higher score = poor)
Only Belanoff 2001 (a four-day trial) reported continuous data
and observed no statistically significant differences between inter-
vention and control (n = 5, 1 RCT, MD -5.20, 95% CI -17.91 to
7.51; Analysis 1.1).
1.1.2 Specific: depression: average endpoint score (HAMD
total, higher score = poor)
Belanoff 2001 also reported continuous data for this outcome and
described no statistically significant differences between interven-
tion and control (n = 5, 1 RCT, MD 1.67, 95% CI -16.44 to
19.78; Analysis 1.2).
1.2 Global state
1.2.1 General - no clinically significant improvement (< 30%
improvement BPRS)
DeBattista 2006 reported very short-term data (immediate) de-
fined as at least a 30% reduction in BPRS scores. They noted no
differences between intervention and control (n = 221, 1 RCT,
RR 1.49, 95% CI 0.93 to 2.38). Twenty-one days after cessation
of the intervention (mifepristone, short-term), DeBattista 2006
assessed this outcome and provided data revealing a difference in
favour of treatment (n = 221, 1 RCT, RR 0.58, 95% CI 0.38 to
0.89; Analysis 1.3) with a number needed to treat for additional
beneficial outcome (NNTB) value of seven.
1.2.2 Specific: positive symptoms - no clinically significant
improvement in BPRS positive symptoms (< 50%
improvement BPRS, PSS)
For the very short term, DeBattista 2006 reported outcome data
defined as at least a 50% reduction in BPRS positive symptom
scores and observed no statistically significant differences between
intervention and control (n = 221, 1 RCT, RR 1.49, 95% CI 0.85
to 2.64). After three weeks, the same study found a statistically
significant difference in favour of treatment (n = 221, 1 RCT, RR
0.60, 95% CI 0.43 to 0.84; Analysis 1.4) with an NNTB value of
five.
1.2.3 Specific: depressive symptoms - no clinically significant
improvement (< 50% improvement HAMD)
Very short-term data fromDeBattista 2006 defined at least a 50%
reduction in HAMD scores as important and reported no statis-
tically significant differences between intervention and control (n
= 221, 1 RCT, RR 1.55, 95% CI 0.84 to 2.84). By three weeks,
no effect was evident (n = 221, 1 RCT, RR 0.83, 95% CI 0.58 to
1.19; Analysis 1.5).
1.2.4 Leaving the study early
Both trials recorded the number of participants leaving the study
early and noted no clear differences between intervention and
control (n = 226, 2 RCTs, RR 1.24, 95%CI 0.77 to 2.01; Analysis
1.6).
1.3 Adverse effects
1.3.1 General: overall number of events
Both trials reported the overall rate of adverse events and observed
no significant differences between intervention and control (n =
226, 2 RCTs, RR 0.92, 95% CI 0.77 to 1.09; Analysis 1.7).
1.3.2 Specific: various effects
DeBattista 2006 reported a long series of adverse events including
allergy, various cardiovascular difficulties, central nervous system
problems, gastrointestinal complaints, metabolic issues and vari-
ous pains. None were prevalent or more common in the mifepri-
stone group (Analysis 1.8).
2. Any antiglucorticoid vs placebo as adjunct to
atypical antipsychotic treatment (data only for
DHEA)
Only Strous 2007, which provided DHEA treatment, could be
included in this comparison (n = 40).
22Antiglucocorticoid and related treatments for psychosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2.1 Mental state
2.1.1 General: average endpoint score (PANSS total, high
score = poor)
Investigators reported no statistically significant differences be-
tween DHEA and control (n = 40, 1 RCT, MD -1.70, 95% CI -
10.78 to 7.38; Analysis 2.1).
2.1.2. Specific: positive and negative symptoms - average
endpoint score (PANSS subscales, high score = poor)
Data from the PANSS negative symptom subscale revealed no sta-
tistically significant differences between intervention and control
(n = 40, 1 RCT, MD 0.70, 95% CI -2.63 to 4.03). This also ap-
plied to the positive subscale (n = 40, 1 RCT, MD -1.00, 95% CI
-3.20 to 1.20; Analysis 2.2).
2.1.3 Specific: negative symptoms and depression (high score
= poor, data skewed)
Data for the SANS were skewed and are presented as ’Other data’
in Analysis 2.3. They do not suggest a clear effect favouring either
approach.
Average depression endpoint scores (CDSS total) were also skewed
but did not clearly favour either group (Analysis 2.4).
2.2 Global state: leaving the study early
Researchers notednodifferences between intervention and control
(n = 40, 1 RCT, RR 0.80, 95% CI 0.25 to 2.55; Analysis 2.5).
2.3 Adverse effects
2.3.1 Extrapyramidal symptoms (EPS) - average endpoint
scores (high scores = poor)
Investigators reported no statistically significant differences be-
tween intervention and control for parkinsonism when using the
SAS (n = 40, 1 RCT, MD 0.00, 95% CI -0.88 to 0.88; Analysis
2.6).
They provided data for other EPS such as akathisia and tardive
dyskinesia but only for the intervention groups (Table 1). They
could undertake no analyses.
2.3.2 Weight gain - average body weight endpoint
Study authors reported no differences between intervention and
control (n = 40, 1 RCT, RR 5.20, 95%CI -4.51 to 14.91; Analysis
2.7).
3. Any antiglucocorticoid vs placebo as adjunct to
combination treatment
Eight trials were included in this comparison involving the follow-
ing intervention treatments: mifepristone (Flores 2006; Gallagher
2005), ketoconazole (Marco 2002), DHEA (Nachshoni 2005;
Ritsner 2006; Ritsner 2010; Strous 2003) and dexamethasone
(Newcomer 1998).
3.1 Mental state
3.1.1 General - average endpoint score - immediate
(BPRS/PANSS total, higher score = poor)
All trials except Newcomer 1998 provided an overall psychotic
symptom score. Data from Nachshoni 2005 were skewed and
therefore are presented as ’Other data’ in Analysis 3.2. For the re-
maining six trials including a total of 171 participants, researchers
reported no overall statistically significant differences between in-
tervention and control for immediate follow-up (n = 171, 6 RCTs,
SMD 0.01, 95% CI -0.29 to 0.32; Analysis 3.1). The test for sub-
group differences was not statistically significant (Chi² = 4.58, df
= 2, P value = 0.10, I² = 56.4%).
a. DHEA
Researchers observed no statistically significant differences be-
tween DHEA and control (n = 106, 3 RCTs, SMD -0.02, 95%
CI -0.40 to 0.37).
b. Ketoconazole
The one trial involving ketoconazole (Marco 2002) showed a sta-
tistically significant difference in favour of control (n = 15, 1 RCT,
SMD 1.15, 95% CI 0.03 to 2.28).
c. Mifepristone
Investigators noted no statistically significant differences between
intervention and control (n = 50, 2 RCTs, SMD -0.21, 95% CI -
0.77 to 0.36).
3.1.2 General: average endpoint score - short term - only
mifepristone (BPRS total, higher score = poor)
Gallagher 2005 conducted follow-up assessment 14 days after ces-
sation of treatment. Study authors described no significant dif-
ferences between intervention and control (n = 20, 1 RCT, MD
2.10, 95% CI -2.86 to 7.06; Analysis 3.3).
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3.1.3 Specific: positive symptoms - average endpoint scores -
immediate (BPRS/PANSS positive subscale, higher score =
poor)
Five of the eight trials provided a measure of positive psychotic
symptoms (Flores 2006;Marco 2002; Ritsner 2006; Ritsner 2010;
Strous 2003). Overall investigators described no statistically sig-
nificant differences between intervention and control (n = 151,
5 RCTs, SMD -0.07, 95% CI -0.40 to 0.25) and no statistically
significant subgroup differences (Analysis 3.4).
3.1.4 Specific: negative symptoms - average endpoint scores -
immediate (PANSS negative subscale, higher score = poor)
Four of the eight trials reported a measure of negative symptoms
(Marco 2002; Ritsner 2006; Ritsner 2010; Strous 2003). Overall,
researchers observed no statistically significant differences between
intervention and control (n = 94, 3 RCTs, MD 2.21, 95% CI -
0.14 to 4.55), but the test for subgroup differences was statistically
significant (Chi² = 7.64, df = 1, P value = 0.006, I² = 86.9%;
Analysis 3.5). Data from Strous 2003 (SANS) were skewed and
are presented as ’Other data’ in Analysis 3.6.
a. DHEA
The two trials (Ritsner 2006; Ritsner 2010) reported no statisti-
cally significant differences between intervention and control (n =
79, 2 RCTs, MD -0.34, 95% CI -3.29 to 2.62), but the test for
subgroup differences was statistically significant (Chi² = 4.41, df
= 1, P value = 0.04, I² = 77%).
b. Ketoconazole
Marco 2002 observed a statistically significant difference in favour
of control (n = 15, 1 RCT, MD 6.49, 95% CI 2.65 to 10.33).
3.1.5 Specific: anxiety symptoms - average endpoint scores -
data only for DHEA (HAMA total, higher score = poor,
skewed data)
Only Strous 2003 reported an anxiety symptom score, but the
data were skewed and are presented as ’Other data’ in Analysis 3.7.
3.1.6 Specific: depression - average endpoint scores - data
only for mifepristone (HAMD total, higher score = poor)
3.1.6.1. Immediate
Four trials provided a depression symptom score. However, data
from three of these trials were skewed and are presented in Analysis
3.9 (Gallagher 2005; Marco 2002; Strous 2003).
In the remaining trial by Flores 2006, study authors noted no sta-
tistically significant differences between intervention and control
(n = 30, 1 RCT, MD -3.20, 95% CI -9.12 to 2.72).
3.1.6.2. Short-term
Gallagher 2005 reported no statistically significant differences be-
tween intervention and control (n = 20, 1 RCT, RR 0.90, 95%
CI -3.75 to 5.55).
3.2 Global state
3.2.1 General - no clinically significant improvement - data
only for mifepristone (< 30% improvement BPRS)
Flores 2006 recorded outcomes as at least a 30% reduction in
BPRS scores and described no statistically significant differences
between mifepristone and control (n = 30, 1 RCT, RR 0.58, 95%
CI 0.32 to 1.06; Analysis 3.10).
3.2.2 Specific - positive symptoms - no clinically significant
improvement - data only for mifepristone (< 50%
improvement BPRS PSS)
Flores 2006 recorded outcomes as at least a 50% reduction in
BPRS positive symptoms subscale scores and described a statis-
tically significant difference in favour of mifepristone (n = 30,
1 RCT, RR 0.38, 95% CI 0.18 to 0.81; Analysis 3.11) with an
NNTB value of two.
3.2.3 Depression - no clinically significant improvement -
data only for mifepristone (< 50% improvement HAMD)
With regards to depression symptoms, and with outcome defined
as at least a 50%reduction inHAMDscores, the short-term trial by
Flores 2006 showed no statistically significant differences between
mifepristone and control (n = 30, 1 RCT, RR 0.85, 95% CI 0.59
to 1.22; Analysis 3.12).
3.2.4 Leaving the study early
Seven trials reported these data (Flores 2006; Gallagher 2005;
Marco 2002;Newcomer 1998; Ritsner 2006; Ritsner 2010; Strous
2003). Four (Gallagher 2005; Marco 2002; Newcomer 1998;
Ritsner 2006) reported no participants leaving the study during
the intervention period. Flores 2006 explained that one person
in the intervention group left the study early, and Strous 2003
reported three people leaving early, all belonging to the placebo
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group. Ritsner 2010 observed that eight people left the study early
- five belonged to the placebo group and three to theDHEA group.
Researchers noted no statistically significant differences between
intervention and control (n = 201, 7 RCTs, RR 0.56, 95% CI
0.20 to 1.52; Analysis 3.13).
a. Dexamethasone
Newcomer 1998 reported that noparticipants left the study during
the intervention period.
b. DHEA
Strous 2003 reported that three people left early, all of whom
belonged to the placebo group. Ritsner 2006 reported that no
participants left the study during the intervention period, and
Ritsner 2010 indicated that five people belonging to the placebo
group left early, along with three people belonging to the DHEA
group.
c. Ketoconazole
Marco 2002 reported that no participants left the study during
the intervention period.
d. Mifepristone
Flores 2006 reported that one person in the intervention group
left the study early. Gallagher 2005 reported that no participants
left the study during the intervention period.
3.3 Cognitive functioning: average endpoint scores, various
tasks
3.3.1 Information processing and sustained attention
Newcomer 1998 observed no statistically significant differences
between intervention and control (n = 19, 1 RCT, MD -0.50,
95% CI -1.87 to 0.87; Analysis 3.14).
3.3.2 Spatial thinking
Newcomer 1998 also noted no statistically significant differences
between intervention and control (n = 19, 1 RCT, MD -0.10,
95% CI -1.63 to 1.43; Analysis 3.14).
3.3.3 Vigilance
Data from Newcomer 1998 were skewed and are presented as
’Other data’ in Analysis 3.15.
3.4 General functioning
3.4.1 Average endpoint scores GAF/SOFAS (low = poor) -
DHEA only
Two trials (Nachshoni 2005; Ritsner 2010) reported these data
and described no statistically significant differences between in-
tervention and control (n = 54, 2 RCTs, MD 1.05, 95% CI -5.55
to 7.66; Analysis 3.16).
3.5 Adverse effects
3.5.1 General: overall number of events
All trials reported the number of general adverse events. Three
trials (Newcomer 1998; Ritsner 2006; Ritsner 2010) reported no
adverse events in the intervention group or in the placebo group.
Overall a statistically significant difference favoured control (n =
223, 8 RCTs, RR 2.66, 95% CI 1.35 to 5.32; Analysis 3.17).
a. Dexamethasone
Newcomer 1998 reported no adverse events in the intervention
group nor in the placebo group.
b. DHEA
Researchers noted no statistically significant differences between
intervention and control (Nachshoni 2005; Ritsner 2006; Ritsner
2010; Strous 2003) (n = 139, 4 RCTs, RR 2.00, 95% CI 0.38 to
10.44). Ritsner 2006 reported no adverse events in the interven-
tion group and none in the placebo group.
c. Ketoconazole
Investigators observed no statistically significant differences be-
tween intervention and control (Marco 2002) (n = 15, 1 RCT, RR
2.19, 95% CI 0.60 to 7.93).
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d. Mifepristone
Study authors described a statistically significant difference in
favour of control (Flores 2006; Gallagher 2005) (n = 50, 2 RCTs,
RR 3.25, 95% CI 1.27 to 8.33) with a number needed to treat
for additional harmful outcome (NNTH) value of seven.
3.5.2 Specific: extrapyramidal symptoms - only DHEA
Nachshoni 2005 reported a statistically significant difference in
favour of DHEA (n = 30, 1 RCT, MD -5.00, 95% CI -8.85 to
-1.15; Analysis 3.18). Similar data in two trials (Ritsner 2006;
Ritsner 2010) were skewed and are presented as ’Other data’ in
Analysis 3.19.
3.5.3 Specific: various effects
Trials presented data for various effects including allergy (skin
rash), blurred vision, dizziness, appetite increase/decrease, fatigue,
irritability, constipation, nausea and dysmenorrhoea. Investigators
described no differences between treatment groups for any of these
adverse effects (Analysis 3.20).
3.6. Quality of life
3.6.1 Observer-rated quality of life scale - DHEA only
Ritsner 2006 assessed general functioning using an observer-rated
QOL scale and noted no statistically significant differences be-
tween intervention and control (n = 55, 1 RCT, MD 6.20, 95%
CI -1.37 to 13.77; Analysis 3.21).
Subgroup analyses - by diagnostic group
The purpose of the remaining comparisons was to assess the
efficacy of each type of intervention treatment across different
diagnoses. All included trials were conducted in people with
schizophrenia/schizoaffective disorder or in individuals with psy-
chotic depression. All five trials (Nachshoni 2005; Ritsner 2006;
Ritsner 2010; Strous 2003; Strous 2007) involving DHEA as
the intervention treatment were conducted in patients with
schizophrenia/schizoaffective disorder; therefore, analysis by diag-
nostic group for DHEA was not possible.
4. Diagnostic group: mifepristone vs placebo as
adjunct to combination treatment
The purpose of this remaining comparisonwas to assess the efficacy
of each type of intervention treatment across different diagnoses.
All included trials were conducted in people with schizophrenia/
schizoaffective disorder or in individuals with psychotic depres-
sion.
Two trials are included in this comparison: Flores 2006 was con-
ducted in people with psychotic depression, and Gallagher 2005
in people with schizophrenia.
4.1. Mental state
4.1.1 General - average endpoint score (BPRS total scores,
higher score = poor)
Both trials provided an overall psychotic symptom score and de-
scribed no statistically significant differences between intervention
and control (n = 50, 2 RCTs, MD -1.02, 95% CI -6.16 to 4.12),
and the test for subgroup diagnostic differences was not statisti-
cally significant (Chi² = 2.79, df = 1, P value = 0.09, I² = 64.2%;
Analysis 4.1).
a. People with psychotic depression
Results show no statistically significant differences between
mifepristone and control (n = 30, 1 RCT, MD -6.80, 95% CI -
15.31 to 1.71).
b. People with schizophrenia/schizoaffective disorder
Study authors reported no statistically significant differences be-
tween mifepristone and control (n = 20, 1 RCT, MD 2.30, 95%
CI -4.15 to 8.75).
4.1.2 Specific a. positive symptoms - average endpoint scores
- people with psychotic depression (BPRS positive subscale,
higher score = poor)
Flores 2006 was the only trial to provide a measure of positive
psychotic symptoms and reported no statistically significant dif-
ferences between intervention and control (n = 30, 1 RCT, MD -
2.60, 95% CI -5.67 to 0.47; Analysis 4.2).
4.1.3 Specific b. depression - average endpoint scores - people
with psychotic depression (HAMD total, higher score = poor)
Only Flores 2006 reported outcome data defined as a 50% or
greater reduction on HAMD scores and no statistically significant
differences between intervention and control (n = 30, 1 RCT,MD
-3.20, 95% CI -9.12 to 2.72; Analysis 4.3).
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4.2 Global state
4.2.1 General - no clinically significant improvement - people
with psychotic depression (< 30% improvement on BPRS)
Only Flores 2006 recorded outcome as at least a 30% reduction
in BPRS scores and no statistically significant differences between
intervention and control (n = 30, 1 RCT, RR 0.58, 95% CI 0.32
to 1.06; Analysis 4.4).
4.2.2 Specific: positive symptoms - no clinically significant
improvement - people with psychotic depression (< 50%
improvement BPRS PSS)
Flores 2006 also recorded outcome as at least a 50% reduction in
BPRS positive symptoms subscale scores and noted a statistically
significant difference in favour of the intervention (n = 30, 1 RCT,
RR 0.38, 95% CI 0.18 to 0.81; Analysis 4.5). with an NNTB
value of two.
4.2.3 Specific: depression - no clinically significant
improvement - people with psychotic depression (< 50%
improvement on HAMD)
Only Flores 2006 provided outcome data defined as at least a 50%
reduction in HAMD scores and showed no statistically significant
differences between intervention and control (n = 30, 1 RCT, RR
0.85, 95% CI 0.59 to 1.22; Analysis 4.6).
4.2.4 Leaving the study early
No participants left the study early in the trial by Gallagher 2005,
and Flores 2006 reportedwas no statistically significant differences
between intervention and control (n = 50, 2 RCTs, RR 3.00, 95%
CI 0.13 to 68.26; Analysis 4.7).
a. People with psychotic depression
Researchers observed no statistically significant differences be-
tween intervention and control (n = 30, 1 RCT, RR 3.00, 95%
CI 0.13 to 68.26).
b. People with schizophrenia/schizoaffective disorder
No participants left the study early in Gallagher 2005.
4.3 Adverse events
4.3.1 Overall number of events
Both trials reported adverse events and noted a statistically signif-
icant difference in favour of control (n = 50, 2 RCTs, RR 3.25,
95% CI 1.27 to 8.33; Analysis 4.8).
a. People with psychotic depression
Study authors described a statistically significant difference in
favour of control (n = 30, 1RCT,RR 4.00, 95%CI 1.41 to 11.35).
b. People with schizophrenia/schizoaffective disorder
Investigators observed no statistically significant differences be-
tween intervention and control (n = 20, 1 RCT, RR 1.00, 95%
CI 0.07 to 13.87).
We could not conduct subgroup analyses on the following because
no or few trials were available: (1) prodrome versus ’first-onset’
versus ’chronic’; (2) type of antiglucocorticoid drug; (3) adults
versus adolescents; and (4) duration of untreated illness.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Any antiglucocorticoid compared with placebo as adjunct to atypical antipsychotic treatment (data only for DHEA) for psychosis
Patient or population: people with psychosis
Settings: inpat ient/ outpat ient
Intervention: any ant iglucocort icoid
Comparison: placebo as adjunct to atypical ant ipsychot ic treatment (data only for DHEA)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo as adjunct to
atypical antipsychotic
treatment (data only
for DHEA)
Any antiglucocorticoid
M ental state: 1. Gen-
eral - average endpoint
score
PANSS total
Follow-up: 12 weeks
Mean mental state: 1.
General - average end-
point score in interven-
t ion groups was
1.7 lower
(10.78 lower to 7.38
higher)
40
(1 study)
⊕⊕©©
Lowa,b
M ental state: 2. Spe-
cific - negative symp-
toms - average end-
point score
PANSS subscale
Follow-up: 12 weeks
Mean mental state:
2. Specif ic - negat ive
symptoms - average
endpoint score in inter-
vent ion groups was
0.7 higher
(2.63 lower to 4.03
higher)
40
(1 study)
⊕⊕©©
Lowa,b
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Global state: general -
no clinically significant
improvement
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome
General functioning:
improved to an impor-
tant degree
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome
Adverse effects: spe-
cific: extrapyramidal
symptoms - aver-
age endpoint scores
parkinsonism
SAS total
Follow-up: 12 weeks
Mean adverse ef fects:
extrapyramidal symp-
toms - average end-
point scores parkin-
sonism in intervent ion
groups was
0 higher
(0.88 lower to 0.88
higher)
40
(1 study)
⊕⊕©©
Lowa,b
Quality of life: im-
proved to an important
degree
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aRisk of bias: rated ’serious’ - small study with some imbalance in groups.
bImprecision: rated ’serious’ - small study.
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Any antiglucocorticoid compared with placebo as adjunct to combination treatment for psychosis
Patient or population: people with psychosis
Settings: inpat ient/ outpat ient
Intervention: any ant iglucocort icoid
Comparison: placebo as adjunct to combinat ion treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo as adjunct to
combination treatment
Any antiglucocorticoid
M ental state: 1. Gen-
eral - average endpoint
score - short term -
only mifepristone
BPRS total
Follow-up: 7 days
Mean mental state: 1.
General - average end-
point score - short term
- only mifepristone in in-
tervent ion groups was
2.1 higher
(2.86 lower to 7.06
higher)
20
(1 study)
⊕⊕©©
Lowa,b
M ental state: 2. Spe-
cific - negative symp-
toms - average end-
point scores - immedi-
ate
PANSS negative sub-
scale
Mean mental state:
2. Specif ic - negat ive
symptoms - average
endpoint scores - im-
mediate in intervent ion
groups was
1.68 higher
(0.93 lower to 4.3
higher)
70
(2 studies)
⊕⊕©©
Lowa,c
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Global state: general
-no clinically signif-
icant improvement -
data only for mifepris-
tone
< 30% improvement on
BPRS
Follow-up: 6 weeks
Lowd RR 0.58
(0.32 to 1.06)
30
(1 study)
⊕©©©
Very lowe,f
700 per 1000 406 per 1000
(224 to 742)
M oderated
800 per 1000 464 per 1000
(256 to 848)
Highd
900 per 1000 522 per 1000
(288 to 954)
Gen-
eral functioning: aver-
age endpoint scores -
data only for DHEA
GAF/ SOFA
Follow-up: 6 weeks
Mean funct ioning: aver-
age endpoint scores -
data only for DHEA in in-
tervent ion groups was
4.4 higher
(3.4 lower to 12.2
higher)
30
(1 study)
⊕⊕©©
Lowe
Adverse effects: 1.
General - overall num-
ber of events
Follow-up: 12 weeks
Lowd RR 2.66
(1.33 to 5.32)
199
(7 studies)
⊕⊕⊕©
M oderatea
50 per 1000 133 per 1000
(67 to 266)
M oderated
100 per 1000 266 per 1000
(133 to 532)
Highd
150 per 1000 399 per 1000
(200 to 798)
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Adverse events: 2.
Specific - extrapyrami-
dal symptoms - aver-
age endpoint scores -
data only for DHEA
SHRS total
Follow-up: 6 weeks
Mean adverse events:
2. Specif ic - extrapyra-
midal symptoms - aver-
age endpoint scores -
data only for DHEA in in-
tervent ion groups was
5 lower
(8.85 to 1.15 lower)
30
(1 study)
⊕⊕©©
Lowe
Quality of life: im-
proved to an important
degree
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aRisk of bias: rated ’serious’ - small study or studies.
bImprecision: rated ’serious’ - few data f rom small study or studies.
cInconsistency: rated ’serious’ - I2 91%.
dModerate risk roughly equates to that of control group.
eRisk of bias: rated ’very serious’ - small t rial, imbalanced groups.
f Indirectness: rated ’serious’ - BPRS not direct measure of global state.
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D I S C U S S I O N
Summary of main results
The review includes data from 11 trials (involving 509 par-
ticipants) that assessed the following antiglucocorticoid and re-
lated treatments: mifepristone, ketoconazole, dexamethasone and
DHEA. The small number of trials in each comparison yielded in-
sufficient evidence to permit definitive conclusions on the efficacy
and safety of these treatments for psychosis as sole treatment or as
an adjunct to regular treatment. Results for each antiglucocorti-
coid or related drug are summarised below. All findings are graded
as of low or very low quality (Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3) with
the exception of adverse events, which are more convincingly in
favour of placebo.
1. Mifepristone
Four trials assessed the efficacy of mifepristone as sole treatment
(n = 225, DeBattista 2006; n = 5, Belanoff 2001) or as an adjunct
to regular treatment (n = 20, Gallagher 2005; n = 30, Flores 2006)
in patients diagnosed with psychotic depression or schizophre-
nia. Analysis of available continuous data showed no beneficial ef-
fect ofmifepristone. For clinical response (dichotomous) variables,
data from Flores 2006 revealed a favourable effect of mifepristone
for clinically significant improvement in positive psychotic symp-
toms, but not in depression symptoms. Dichotomous data from
DeBattista 2006 showed no differences between intervention and
control immediately post intervention; however at 21 days’ follow-
up, they revealed a beneficial effect of mifepristone for total and
positive psychotic symptoms, but not for depression symptoms.
All trials reported the rate of general adverse events (refer to Table
2 for a detailed description) and provided evidence for a higher
rate of general adverse events with treatment. Only Flores 2006
stated that researchers observed no serious adverse events.
Too few trials were identified to investigate the efficacy of mifepri-
stone treatment across diagnostic groups or the optimal method of
treatment (e.g. single or adjunctive therapy, length of treatment).
2. Ketoconazole
One trial (n = 15, Marco 2002) assessed the efficacy of ketocona-
zole, a cortisol synthesis inhibitor, as an adjunct to regular treat-
ment in patients with schizophrenia/schizoaffective disorder. Data
from this small trial show no benefit from treatment and in some
cases a more favourable outcome with placebo. Study authors de-
scribed no adverse events in the intervention group and none in
the placebo group.
3. DHEA
Five trials assessed the efficacy of DHEA as an adjunct to atypical
antipsychotic (n = 40, Strous 2007) or combination treatment (n =
62,Ritsner 2006; n=32,Ritsner 2010; n=30, Strous 2003; n=34,
Nachshoni 2005) in patients with schizophrenia or schizoaffective
disorder. A large proportion of the data were skewed and therefore
could not be included in the meta-analysis. Data available for
analysis showed no evidence for an effect of treatment on clinical
symptoms. The rate of participant attrition or general adverse
events did not differ betweenDHEA treatment and placebo.With
regards to extrapyramidal symptoms, Nachshoni 2005 revealed
a beneficial effect of treatment, whereas Strous 2007 showed no
effect of treatment.
4. Dexamethasone
Noprimary outcome data were provided in the trial involving dex-
amethasone treatment (Newcomer 1998), and no evidence sug-
gested an effect of dexamethasone treatment on cognitive func-
tioning.
Available data were insufficient for comparison of the effects of
intervention treatment in the following subgroups: (1) ’prodrome’
versus ’first-onset’ versus ’chronic’; (2) type of antiglucocorticoid
drug; (3) adults versus adolescents; and (4) duration of untreated
illness.
Overall completeness and applicability of
evidence
Only short-term outcomes (up to 12 weeks) were assessed, and
most studies measured outcomes immediately following cessation
of the intervention. Three trials conducted follow-up assessments
up to a maximum of 21 days post treatment and provided scant
data on general functioning; however, this aspect would be more
relevant to trials with longer follow-up assessments.
All trials were conducted in adult populations, primarily with a
diagnosis of schizophrenia or schizoaffective disorder (eight of 11
trials). The remaining three studies were conducted in people with
psychotic depression, and all trials involved mifepristone treat-
ment. Some trials required a specified level of symptom severity
for entry into the trial. No trials were conducted in patients at their
first episode of psychotic illness and none included populations at
high risk for developing psychosis.
Quality of the evidence
The quality of data was variable. Most trials included fewer than
40 participants, with the exception of DeBattista 2006 (n = 225)
and Ritsner 2006 (n = 62). Just over half of the trials (seven of 11)
used adequate randomisation, allocation concealment and blind-
ing. It should be noted however that in some of these trials, it was
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necessary to request this information from the study authors be-
cause it was not adequately described in the publication. The re-
maining four trials did not adequately describe the randomisation
and allocation procedures and therefore have unclear risk of bias.
Most participants were followed up, or intention-to-treat analysis
was conducted. A large proportion of available data, particularly
regarding depression symptoms, was skewed and therefore could
not be included in the meta-analysis. Other risks of bias involved
small sample size, and in some trials baseline imbalances in clinical
symptom scores were apparent between intervention and control
groups (refer to Table 2). Analysis of final endpoint data in this
review, as opposed to change scores, may have biased the results.
Potential biases in the review process
We tried to identify all relevant trials in our search. However,
we may not have identified all studies. We are aware that the
search date is old at the time of publication and new studies may
be available. Our review has been limited to articles written in
English, so bias may involve including no studies published in
languages other than English.
Agreements and disagreements with other
studies or reviews
Strous 2003 and Strous 2007 reported an improvement in nega-
tive symptoms and/or depression and in anxiety symptoms with
dehydroepiandrosterone (DHEA) treatment. In contrast, results
of this review show no evidence for a beneficial effect of DHEA
treatment on clinical symptoms. In partial agreement with this
review, the 12-week cross-over trial by Ritsner 2006 reported no
significant clinical improvement with DHEA treatment, although
the first six weeks of DHEA treatment was associated with sig-
nificant improvement in Positive and Negative Syndrome Scale
(PANSS) scores compared with placebo. These discrepancies are
likely due to the type of data analysed (e.g. change scores vs final
endpoint data) and the fact that data were skewed and were not
included in the meta-analyses.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
This review suggests that little trial-based evidence shows the ef-
fectiveness of antiglucocorticoid and related medications in treat-
ing individuals with psychosis. People with psychosis should con-
tinue to look at new trials and reviews in this area, as this review
suggests that mifepristone may be effective, and with more trials,
its effectiveness may be established in the future.
2. For clinicians
Given the lack of data at this stage, antiglucocorticoid treatments
cannot be recommended. Very few trials have been conducted, and
most have involved a small sample. Limited available data do not
provide enough evidence to support or refute the use of antigluco-
corticoid treatment for psychotic disorders, although some find-
ings suggest a favourable effect for mifepristone. Additional trials
are needed.
3. For managers or policy makers
Managers and policy makers have little evidence upon which to
base decisions about provision of these medications.
Implications for research
1. General
Some trials appeared to follow the CONSORT statement and
offered clear reporting of the conduct of the trial, but this was not
the case in all studies, and clearer reporting would have allowed
this review to be more informative. Particularly disappointing was
the lack of reporting of useable outcome data.
2. Specific
2.1 Reviews
Suggestions for future reviews include the neurosteroid preg-
nenolone, which is synthesised from cholesterol and is a precursor
to glucocorticoids. Pregnenolone enhances learning and memory
in rodents, and clinical trials are now being conducted to inves-
tigate adjunctive pregnenolone for cognitive and negative symp-
toms in patients with schizophrenia or schizoaffective disorder. See
also Table 3.
2.2 Trials
Well-designed, larger-scale trials are needed across the range of
psychotic disorders and at different stages of illness. In particu-
lar, there is a need to investigate these types of treatments in at-
risk and early psychosis populations. Treatments aimed at correct-
ing HPA axis dysfunction might be more effective at early stages
of illness, during which hyperactivity of the HPA axis is thought
to be pronounced. These trials need to include outcome mea-
sures such as time to transition to psychosis and transition rate,
along with assessment of clinical symptoms and general function-
ing. Neuroendocrine measurements and/or screening of patients
with demonstrable HPA axis dysfunction for inclusion in the trial
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would be useful for deliveringmore targeted treatment. Trials with
longer follow-up assessments are needed to determine the short-,
medium- and long-term outcomes of these treatments. It will be
important to assess levels of social and occupational functioning,
which often are considered more pertinent to the clinician and
patient than symptom reduction alone. Finally, trials need to fol-
low CONSORT guidelines for reporting data from clinical trials
(Table 4).
A C K N OW L E D G E M E N T S
The Cochrane Schizophrenia Group maintains a standard tem-
plate for the Methods section, and we have used and adapted this
for our requirements.
We would like to thank Muayad Alzuabi for peer review and Do-
lores Matthews for copy editing.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Belanoff 2001
Methods Allocation: randomised.
Blindness: participant/personnel, unclear whether blinded at outcome.
Duration: 4 days.
Design: cross-over (× 1).
Participants Diagnosis: major depression with psychotic features. DSM IV, clinician interview(s).
N = 5.
Age: range 44 to 67 years; average mifepristone ~ 48 (SD 4), placebo 56 (SD ~ 12) years
(first arm)
Sex: 3 M, 2 F (first arm).
Setting: inpatient.
History: duration of illness - mifepristone 4.5 months (SD ~ 5), placebo 98 months (SD
123)
Excluded: any sign of Cushing syndrome apart from hypercortisolaemia, women of
child-bearing potential, patients using illicit drugs within a month before admission,
patients consuming up to 2 ounces of alcohol daily
Country: USA.
Interventions 1. Mifepristone: dose 600 mg/day. N = 2.
2. Placebo: N = 3.
Other concurrent treatments: no antipsychotic medication for 3 days before entering
study, no antidepressant upon entering study, no participants started on antidepressant
medication while in study, benzodiazepines permitted for insomnia and acetaminophen
for headaches
Outcomes Mental state: total psychotic symptoms (BPRS), depression (HAMD total score)
Global state: leaving the study early.
Adverse event: overall adverse event rate.
Unable to use: cognition paragraph recall (not reported).
Notes All means and SDs were calculated from individual data by BG
Funded by NARSAD Young Investigator Award, Pritzker Foundation, NIMH
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Randomised”; no other statement pro-
vided. Imbalance in duration of illness be-
tween groups calls into question the success
of randomisation
Allocation concealment (selection bias) Unclear risk Unclear - no statement provided.
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Belanoff 2001 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “..patients served as their own controls
in a random-assignment, double-blind
crossover design” (pg 517)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) High risk Two outcome measures not reported in the
results: Clinical Global Impression (CGI)
scale, paragraph recall cognitive test
Other bias High risk Small sample size (n = 5).
DeBattista 2006
Methods Allocation: randomised.
Blindness: participant/personnel, unclear whether blinded at outcome
Duration: 7 days.
Assessment points: baseline (day 0), daily during dosing (days 1 to 7), days 14 and 28
Participants Diagnosis: psychotic depression. Structured Clinical Interview for DSM Disorders
(SCID), DSM IV, clinician interview(s).
N = 221.
Age: mifepristone group mean ~ 41 years (SD ~ 11), placebo group mean ~ 42 years
(SD 11).
Sex: 112 M, 109 F.
Setting: inpatient and outpatient.
History: unclear.
Excluded: unstable medication condition, use of systemic or inhaled corticosteroids,
ECT in past 3 months, antidepressant and/or antipsychotic in past 7 days, history of
illicit drug use in past month, alcohol or drug dependence in past 6 months
Country: USA (29 sites).
Interventions 1. Mifepristone: dose 600 mg/day. N = 105.
2. Placebo: N = 116.
Other concurrent treatments: antipsychotics and antidepressants not allowed for 7 days
of study, thereafter any indicated treatment
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DeBattista 2006 (Continued)
Outcomes Global state: rapid response (> 30% reduction BPRS total at days 7 and 28), response
(> 30% reduction BPRS total at day 28 but not at day 7), positive psychotic response (<
50% improvement BPRS PSS) and depression response (< 50% improvement HAMD)
Leaving the study early.
Adverse events: spontaneous report of adverse events.
Notes Funded by: This work was sponsored by Corcept Therapeutics, Menlo Park, California.
“We acknowledge the following disclosures; CD: Speakers Bureau, Wyeth, Cephalon,
Pfizer, GSK, Lilly, BMS, Cyberonics. Grant support; Wyeth, GSK, Cephalon, Pritzker
Foundation, NARSAD, NIMH, Neuronetics, Cyberonics. Consultant; Corcept Thera-
peutics, Wyeth, Lilly, Roche, BMS. Stock-holder; Corcept Therapeutics. JB: CEO and
equity-holder; Corcept Therapeutics, Menlo Park, CA. CB: Statistical consultant; Cor-
cept Therapeutics. LLC: Consultant; GlaxoSmithKline, Novartis, Pfizer, Johnson &
Johnson, Sepracor, Cyberonics, Bristol-Myers Squibb, Medronic, and Wyeth. Grants/
Research support; NIH, US Dept of the Interior, Cyberonics, Pfizer, Corcept Thera-
peutics, Medtronic, and UCB Pharma. Speakers Bureau or has received Honoraria for
speaking; Cyberonics, Pfizer, Wyeth, AstraZeneca, and Cephalon.”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients who met the study criteria were
randomised 1:1 to 7 days...” (pg 1344)
Allocation concealment (selection bias) Unclear risk Unclear - no statement provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “randomised 1:1 to 7 days of
inpatient treatment in a double-blind,
placebo controlled, parallel group design”
(pg 1344)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed using appropriate
methods (ITT analysis conducted)
Selective reporting (reporting bias) Low risk All outcome measures reported.
Other bias High risk Study authors have conflict of interest with
sponsor/funding source
43Antiglucocorticoid and related treatments for psychosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Flores 2006
Methods Allocation: randomised.
Blindness: double.
Duration: 8 days.
Participants Diagnosis: psychotic major depression, SCID, DSM IV and clinician interview(s).
N = 31.
Age: mean - mifepristone group ~ 36 years (SD ~ 13), placebo group ~ 39 years (SD ~
13).
Sex: 13 M, 17 F.
Setting: inpatient and outpatient.
History: unclear.
Excluded: pregnant/lactating women, major medical illnesses, history of seizures, major
head trauma, abnormal clinical laboratory tests, those taking systemic steroids, people
younger than 18 years, actively suicidal, obsessive-compulsive disorder
Country: USA.
Interventions 1. Mifepristone: dose 600 mg/day. N = 17.
2. Placebo: N = 15.
Other concurrent treatments: remained on current medications during study (included
antidepressants, antipsychotics, anxiolytics, mood stabilisers)
Outcomes Mental state: total psychotic symptoms (BPRS), positive psychotic symptoms (BPRS
positive symptoms subscale), depression (HAMD total score)
Global state: response (30% reduction BPRS total and 50% reduction BPRS positive)
Leaving the study early.
Adverse events: overall rate, serious adverse outcomes.
Notes Funded by National Institute of Mental Health and National Institutes of Health. “Cor-
cept Therapeutics has licensed intellectual property for the use of mifepristone in the
treatment of PMD. Dr Alan Schatzberg is cofounder of Corcept Therapeutics and is the
only author involved in this submission who has any financial interest in this company.
However, Dr Schatzberg continues to be full-time faculty at Stanford University. In ad-
dition, Dr Schatzberg played no direct role in the recruitment, assessment, or follow-up
of subjects enrolled in this study. Dr Schatzberg was not directly involved in the analysis
of data stemming from this research.”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “..patients were randomised to...” (pg.630)
.
Allocation concealment (selection bias) Unclear risk No statement provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Patients were randomised to either
600mg per day of double-blind mifepris-
tone or placebo for eight days” (pg 630)
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Flores 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients were randomised to either
600mg per day of double-blind mifepris-
tone or placebo for 8 days” (pg 630)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients were rated on the HDRS
and BPRS by a blinded, trained clinical ad-
ministrator...” (pg 630)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk One participant dropped out during the
intervention and was not included in the
analysis
Selective reporting (reporting bias) Low risk All outcome measures were reported.
Other bias Unclear risk One study author has financial interest in
the company that has licensed IP for use of
mifepristone in treatment of PMD
Gallagher 2005
Methods Allocation: randomised.
Blindness: double.
Duration: 7 days.
Participants Diagnosis: schizophrenia, SCID, DSM IV.
N = 20.
Age: average 43 years (SD 9.6), range 27 to 61 years.
Sex: 18 M, 2 F.
Setting: outpatient.
History: unclear.
Excluded: women of child-bearing potential, neuropsychological confounds of previous
major head injury, current or previous neurological disease, co-morbidmedical condition
Country: UK.
Interventions 1. Mifepristone: dose 600 mg/day. N = 10.
2. Placebo: N = 10.
Other concurrent treatments: “Patients’ medication had been unchanged for six weeks
before participation and remained so throughout the study period. Two subjects had
minor dose reductions during the previous eight weeks, but otherwise there had been no
medication changes for at least eight months.” All 20 participants were taking at least 1
antipsychotic (see details, p 157). In addition, 7 were taking anticholinergics, 1 carba-
mazepine, 6 an antidepressant, 1 regular paracetamol, 1 ibuprofen and 1 carbimazole
Outcomes Mental state: total psychotic symptoms (BPRS), depression post intervention, and de-
pression at follow-up (HDRS-17)
Global state: leaving the study early.
Adverse events: general adverse events.
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Gallagher 2005 (Continued)
Unable to use cognitive functioning: spatial working memory task (CANTAB), Rey-Au-
ditory Verbal Learning Test, short-term memory span, visuospatial learning and mem-
ory, executive function and attention. Cross-over study design: data not reported for the
first phase of the study. Study authors reported no significant differences between groups
in any cognitive measure
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (from correspondence): “Using a
computerised randomiser for trial design.”
Allocation concealment (selection bias) Low risk Quote (from correspondence): “It was held
by pharmacy and was not known to anyone
involved in the study. All medication was
dispensed by pharmacy in identical packag-
ing, and active/placebos were identical and
produced by the manufacturer (Exelygen).
”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Administration of medication was in a
double-blind design” (pg 156). Outcome
assessors were blind (source: correspon-
dence)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Administration of medication was in a
double-blind design” (pg 156)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blind (source: corre-
spondence).
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data for phase 1 of
cross-over trial. Only data from phase 1 in-
cluded in the meta-analysis
Selective reporting (reporting bias) Low risk All outcome measures reported.
Other bias Low risk Study appears to be free of other sources of
bias.
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Marco 2002
Methods Allocation: randomised.
Blindness: unclear.
Duration: 4 weeks.
Funded byNARSAD, theNational Alliance for theMentally Ill, the Stanley Foundation.
Active ketoconazole and placebo capsules were provided at no cost by Janssen Pharma-
ceuticals
Participants Diagnosis: schizophrenia or schizoaffective disorder, SCID, DSM III-R.
N = 19.
Age: average 48 year (SD 8.5), range 33 to 62 years.
Sex: 12 M, 3 F.
Setting: outpatient.
History: unclear.
Excluded: no change in medication in the past 6 weeks, medically unhealthy, no use of
other steroid-containing medications
Country: USA.
Interventions 1. Ketoconazole: started at 200 mg/day and advanced to maximum dose 800 mg/day.
N = 8
2. Placebo: N = 7.
Other concurrent treatments: All participants were taking stable doses of antipsychotic
medication (including risperidone, perphenazine, haloperidol decanoate and thiori-
dazine) and, when applicable, antidepressant and/or mood stabiliser medication (includ-
ing clonazepam, lithium, trazodone, benztropine mesylate, diphenhydramine, propra-
nolol, carbamazepine, sucralfate, sertraline, lorazepam and trihexyphenidyl). One par-
ticipant with schizophrenia was taking no concurrent treatment. As a criterion of clinical
stability, all participants were well known to the outpatient psychiatry clinic and had not
required any change in medication dosage for a minimum of 6 weeks. No changes in pre-
stabilised, open-label antipsychotic, antidepressant and/or mood-stabilising medication
regimens were allowed during the study period
Other concurrent treatments (placebo group): All participants were taking stable doses
of antipsychotic medication (including risperidone, haloperidol, perphenazine and tri-
fluoperazine) plus, when applicable, antidepressant and/or mood stabiliser medication
(including paroxetine, lorazepam, benztropine mesylate, diphenhydramine, fluoxetine,
buspirone and methylphenidate). Two participants with schizophrenia were taking no
concurrent treatment
Outcomes Mental state: total psychotic symptoms (PANSS), positive psychotic symptoms (PANSS)
, negative psychotic symptoms (PANSS), depression (HAMD)
Global state: leaving the study early.
Adverse events: general adverse events.
Unable to use: cognition. California Verbal Learning Test, Trails A & B, FAS Verbal
Fluency Test. Alternate versions of the CVLT and Verbal Fluency Test were used for
baseline and week 4 assessments. Data were not provided. Study authors reported no
significant differences between groups on cognitive measures
Notes
Risk of bias Risk of bias
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Marco 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (from correspondence): “by com-
puter sequence.”
Allocation concealment (selection bias) Low risk Quote (from correspondence): “Envelopes
with key based on numeric code. Pharma-
cist had filled blinded Rx based on numeric
code.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participant/providers: Yes. Quote: “Sub-
jects were randomised to receive in a dou-
ble-blind manner...” (pg 157)
Outcome assessors: Yes. Quote: “Subjects
and blinded raters were not able to accu-
rately guess treatment assignment based on
side effects.” (pg 159)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Subjects and blinded raters were
not able to accurately guess treatment as-
signment based on side effects” (pg 159)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) High risk Data reported only for HAMD and corti-
sol measures. For PANSS, BDI, Bunney-
Hamburg Global Rating Scale and neu-
rocognitive function tests, it was stated that
no significant differences were noted (data
not reported)
Other bias High risk Baseline gender imbalance. Participants in
the ketoconazole group seem to be taking
a greater number of concomitant medica-
tions, suggesting that they may have more
severe or complex illness. Those in the ke-
toconazole group had higher baseline cor-
tisol levels
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Nachshoni 2005
Methods Allocation: randomised.
Blindness: double.
Duration: 7 days.
Funded by: no extramural funding (source: study author).
Participants Diagnosis: schizophrenia, schizoaffective disorder. SCID, DSM III-R.
N = 34.
Age: average ~ 40 years (SD ~ 12), range 19 to 64 years.
Sex: 23 M, 7 F.
Setting: inpatient.
History: unclear.
Excluded: receiving steroids, pregnant women, patients engaged in substance abuse,
patients with significant medical or neurological illness
Country: Israel.
Interventions 1. DHEA: dose 100 mg/day( 50 mg bid at 8am and 8pm). N = 18.
2. Placebo: N = 16.
Other concurrent treatments: All participants had received fixed doses of antipsychotic
medications for at least 3 weeks before study commencement, and no change in dosage
or medication was permitted for the trial duration. Anti-EPS agents were withdrawn
with a 2-day washout period before randomisation
Outcomes Mental state: total psychotic symptoms (BPRS).
General functioning: GAF.
Adverse events: general adverse events and general extrapyramidal symptoms (SHRS)
Unable to use: adverse events - extrapyramidal symptoms - UKU (not reported)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “subjects were randomised (by
means of random number generation)...”
(pg 252)
Allocation concealment (selection bias) Low risk Quote (from correspondence): “Random-
ization numbers provided by statistician to
research assistant assigning study medica-
tion and maintained under lock and key in
concealed fashion.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participant/providers: Yes. Quote: “...ran-
domised to receive either DHEA at a fixed
dose of 100 mg/day or placebo in double-
blind fashion...” (pg 252)
Outcome assessors blind (from correspon-
dence).
49Antiglucocorticoid and related treatments for psychosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nachshoni 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blind (from correspon-
dence).
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing outcome data for 4 participants
not accounted for in analysis
Selective reporting (reporting bias) High risk Study authors unable to analyse tardive
dyskinesia or dystonia because few partici-
pants had tardive dyskinesia (10%) or dys-
tonia (0%). UKU scores not reported
Other bias High risk Only 11/30 participants
exhibited akathisia, and slight differences
in baseline akathisia symptoms were noted
between groups. Sample size was small and
the intervention was of short duration
Newcomer 1998
Methods Allocation: unclear.
Blindness: unclear.
Duration: 4 days.
Funded by NIMH Scientist Development Awards.
Participants Diagnosis: schizophrenia. DMS III-R and clinician interview.
N = 19.
Age: average ~ 32 years (SD 8).
Sex: 9 M, 10 F.
Setting: inpatient.
History: unclear.
Excluded: history of DSM-III-R substance dependence or abuse within the past 6
months, current pregnancy, any current medical illness including trauma, fever or dehy-
dration in the past month, neurological disorders (except possible tardive dyskinesia) in-
cluding any history of significant head injury, defined as loss of consciousness for longer
than 5 minutes and/or with neurological sequelae. Body weight < 80% of ideal body
weight, treatment with narcotics in the past month, any treatment with corticosteroids
or high-dose oestrogens within past 6 months
Country: USA.
Interventions 1. Dexamethasone: successive doses of 0.5, 1, 1 and 1 mg at 2300 h on days 0 to 3. N
= 11
2. Placebo: N = 8.
Other concurrent treatments: Participants were studied during ongoing ’typical’ antipsy-
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Newcomer 1998 (Continued)
chotic treatment, including haloperidol and adjunctive anticholinergics. They were also
studied during ongoing nicotine use
Outcomes Global state: leaving the study early.
Cognitive function: paced serial addition task, vigilance task, Benton line orientation
task
Adverse events: spontaneous reporting of adverse events.
Unable to use: mental state. Total psychotic symptoms (BPRS not reported), negative
psychotic symptoms (SANS not reported)
Cognitive functioning: paragraph recall test (data not available)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No statement provided.
Allocation concealment (selection bias) Unclear risk No statement provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “...after 4 days of double-blind,
placebo controlled treatment with DEX...
” (pg 67)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses excluded participants with miss-
ing data (n = 3). However,Quote: “analyses
were also run that included all subjects (n=
19) by applying conservative adjustments
for missing data (mean performance values
for the other three test days as the washout
(day 11) performance value).”
Selective reporting (reporting bias) High risk Only baseline BPRS and SANS scores re-
ported.
Other bias High risk Participants in placebo group received on
average lower dose of antipsychotic medi-
cation compared with intervention group
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Ritsner 2006
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks.
Funded by Stanley Foundation.
Participants Diagnosis: schizophrenia or schizoaffective disorder. SCID, DSM IV.
N = 62.
Age: average ~ 36 years (SD 10), range 20 to 53 years.
Sex: 41 M, 14 F.
Setting: inpatient and outpatient.
History: length of illness - “chronic” average ~ 14 years (SD ~ 9).
Excluded: evidence of organic brain damage, mental retardation, major medical illness,
alcohol or drug abuse, prostate nodules or cancer; symptoms of benign prostatic hyper-
trophy, pregnant women, history of breast or uterine illness
Country: Israel.
Interventions 1. DHEA first: 100 mg BID (total 200 mg/day). N = 29.
2. Placebo first: N = 26.
Other concurrent treatments: Throughout duration of study, participants continued
to receive regular antipsychotic medication, with antipsychotic medication dose kept
constant for at least 2 weeks before study entry and throughout the study period
24 participants received first-generation antipsychotic medication: chlorpromazine
equivalent mean dose of 660 mg/d (SD 53)
20 received second-generation antipsychotic medication: chlorpromazine equivalent
mean dose of 375 mg/d (SD 266)
11 received both types of antipsychotic medication: chlorpromazine equivalent mean
dose of 1077 mg/d (SD 357)
Participants allowed to receive benzodiazepine or antiparkinsonian medications as indi-
cated
Outcomes Mental state: total psychotic symptoms (PANSS), positive psychotic symptoms (PANSS)
, negative psychotic symptoms (PANSS)
Global state: leaving the study early.
General functioning: observer-rated QOL scale.
Adverse events: extrapyramidal symptoms (ESRS, AIMS).
Unable to use: cognitive functioning. CANTAB including visual and movement skills,
attention andmemory and executive function. Cross-over study design: data not reported
for first phase of the study. Study authors reported significant improvement in visual
sustained attention, visual andmovement skills followingDHEAcomparedwith placebo.
They noted no significant differences between groups in the other cognitive domains
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (from correspondence): “Indepen-
dent pharmacist dispensed eitherDHEAor
52Antiglucocorticoid and related treatments for psychosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ritsner 2006 (Continued)
placebo capsules according to a computer
generated randomization list.”
Allocation concealment (selection bias) Low risk Quote (from correspondence): “the alloca-
tion was done by a pharmacist.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participant/providers: participants,
providers and key study personnel blinded
(source: correspondence)
Outcome assessors: yes (from correspon-
dence).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, providers and key study per-
sonnel blinded (source: correspondence)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded (source: corre-
spondence).
Incomplete outcome data (attrition bias)
All outcomes
High risk Number dropped out during intervention:
7. Quote: “..seven patients failed to com-
plete the 12 weeks of the crossover ran-
domisation phase because of withdrawal of
study consent after randomisation, but pre-
viously have received the first dose of study
medication” (pg 497)
Analyses excluded participants with miss-
ing data (n = 7).
Selective reporting (reporting bias) Low risk All outcome measures reported.
Other bias Low risk Study appears to be free of other sources of
bias.
Ritsner 2010
Methods Allocation: randomised.
Blindness: double.
Duration: 8 weeks.
Funding: none reported.
Participants Diagnosis: schizophrenia or schizoaffective disorder. SCID, DSM IV.
N = 58.
Age: average 35.8 years (SD 8.3), range 23 to 55 years.
Sex: 32 M, 12 F.
Setting: outpatient.
History: average duration of illness (years): PREG30 = 15.1 (8.0); PREG200 = 11.7 (7.
7); DHEA400 = 10.3 (7.3); placebo = 11.1 (6.5).
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Ritsner 2010 (Continued)
Excluded: unstable medical condition, any significant medical (including prostate ill-
ness) or neurological illness, pregnant women, receiving mood stabilisers or any steroid
hormonal supplement (e.g. oestrogen)
Country: Israel.
Interventions 1. Pregnenolone (PREG30) 30 mg/day. yN = 16.
2. Pregnenolone (PREG200) 200 mg/day. N = 10.
3. DHEA 400 mg/d. N = 16.
4. Placebo identical capsules. N = 16.
Other concurrent treatments: antipsychotic, anticholinergic, benzodiazepine medication
continued from before the trial
PREG30: chlorpromazine equivalent 476.4 (337.6) mg/day.
PREG200: chlorpromazine equivalent 585.0 (704.3) mg/day.
DHEA: chlorpromazine equivalent 441.1 (276.2) mg/day.
Placebo: chlorpromazine equivalent 621.3 (455.3) mg/day.
Outcomes Mental state: total psychotic symptoms (PANSS), positive psychotic symptoms (PANSS)
, negative psychotic symptoms (PANSS)
Global state: leaving the study early.
General functioning: GAF.
Adverse events: general adverse events, extrapyramidal symptoms (ESRS, BARS)
Unable to use: cognitive functioning. CANTAB including matching to sample (MTS),
delayed matching to sample (DMS), pattern recognition (PRM), rapid visual informa-
tion processing (sustained attention) (RVP) and stockings of Cambridge (SOC). Data
not provided. Study authors reported significant improvement in DMS and MTS with
pregnenolone 30 mg/d treatment. No significant effects of DHEA on cognitive function
reported
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization procedure was per-
formed using the Random Allocation Soft-
ware, version 1.0” (pg 1353)
Allocation concealment (selection bias) Low risk “The pharmacist conducted randomiza-
tion of participants by using a random
and equal block size for placebo, DHEA
and PREG30 arms (with ratio 1.5:1 for
PREG30 and PREG200 arms, respec-
tively) and conducted blinding of the trial.
The patient allocation details were coded
and kept confidential until the trial was
completed” (pg 1353)
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Ritsner 2010 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind study design” (pg 1352).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind study design” (pg 1352).
Participants and study personnel blinded.
“The patient allocation details were coded
and kept confidential until the trial was
completed” (pg 1353)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded (pg 1353).
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk LOCF analysis described in methods (pg
1354): “Patients who completed the study
(completers) were included in the statistical
analysis. The LOCF procedure was used
to analyze those subjects who completed at
least four weeks (selected a priori) but failed
to complete all eight weeks of the study
(non-completers)”
(pg 1365): “Of the 58 patients ran-
domly assigned to this trial, 14 patients
dropped out.” “More specifically 1,1,2, and
3 patients assigned to receive PREG-30,
PREG-200, DHEA, and placebo, respec-
tively, dropped out between four and six
weeks, and seven patients dropped out be-
tween six and eight week.”
All 14 participants who left the the study
early had completed at least 4 weeks of the
trial. However, analysis was performed on
44, not LOCF (n = 58)
Reasons for leaving the study early included
lack of efficacy (n = 4), change in antipsy-
chotic drugs (n = 3), loss to follow-up (n =
5), non-compliance (n = 2)
Selective reporting (reporting bias) Low risk All outcomes reported.
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Strous 2003
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks.
Funded by NARSAD Young Investigator Award.
Participants Diagnosis: schizophrenia. SCID, DSM III-R.
N = 30
Age: average ~ 37 years (SD 12), range 20 to 67 years.
Sex: 12 M, 15 F.
Setting: inpatient.
History: duration of illness “chronic”, average ~ 200 months (SD 130).
Excluded: any significant medical (including prostate illness) or neurological illness,
pregnant women, patients administered mood stabilisers or any steroid or hormonal
supplement (e.g. oestrogen)
All participants entered a 1-week, single-blind, placebo lead-in phase of the study. Partic-
ipants completing the placebo lead-in who continued to demonstrate the above criteria
for negative symptoms, with no meaningful change in SANS score (defined by a change
> 20% in clinical ratings score), qualified to enter study treatment phase
Country: Israel
Interventions 1. DHEA: dose 25 mg/d for first 2 weeks (8am), 50 mg/day in equally divided doses for
the following 2 weeks (8am and 8pm), then 100 mg/d in equally divided doses for the
final 2 weeks (8am and 8pm). N = 15
2. Placebo: N = 15.
Other concurrent treatments: Participants were required to have been administered a
stable dose of their current ’typical’ or ’atypical’ antipsychotic medication for at least a
month before study commencement. Participants were required to continue taking their
regular medications for the duration of the study. No change in dose or addition of any
other psychoactive medication was permitted during the study. All participants entered
a 1-week, single-blind, placebo lead-in phase of the study. Five individuals were taking
olanzapine, 4 clozapine, 3 haloperidol, 1 fluphenazine, 1 zuclophenthixol and 1 risperi-
done. Four participants were taking benzodiazepine medication, and 3 anticholingeric
medication
Outcomes Mental state: total psychotic symptoms (PANSS), positive psychotic and negative symp-
toms (PANSS, SANS), depression (HAMD total score), anxiety (HAMA)
Global state: leaving the study early.
Adverse events: overall rate, monitored and assessed daily for any adverse events, formally
assessed weekly by a physician for any DHEA medication adverse effects
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were then randomised (by
means of random number generation) to
receive...” (pg 134)
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Strous 2003 (Continued)
Allocation concealment (selection bias) Low risk Quote (from correspondence): “Randomi-
sation numbers provided by statistician to
research assistant assigning study medica-
tion and maintained under lock and key in
concealed fashion.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participant/providers: yes. Quote: “..to re-
ceive either DHEA or placebo, each for six
weeks in a double-blind manner (adminis-
tered and monitored by a hospital pharma-
cist)” (pg 134)
Outcome assessors blinded (Source: corre-
spondence).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded (source: corre-
spondence).
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number leaving early during intervention:
3 participants (DHEA = 0; placebo = 3)
eliminated from study analysis after fail-
ing to complete 3 weeks of randomisation
phase (selected a priori). Missing data on 4
participants (DHEA = 2; placebo = 2) im-
puted using LOCF
Three participants eliminated from study
analysis after failing to complete 3 weeks
of randomisation phase (selected a priori)
. Missing data on 4 participants imputed
using LOCF
Selective reporting (reporting bias) Low risk All outcome measures reported.
Other bias High risk Gender imbalance. No data given on num-
ber of individuals screened for study inclu-
sion
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Strous 2007
Methods Allocation: randomised.
Blindness: double.
Duration: 12 weeks.
Funded by NARSAD Young Investigator Award.
Participants Diagnosis: schizophrenia. DSM IV, SCID.
N = 40.
Age: average 34 years (SD ~ 10), range 18 to 58 years.
Sex: 27 M 13 F.
Setting: inpatient.
History: duration of illness ’chronic’, longer than 2 years.
Excluded: people with any significant medical (including prostate illness) or neurological
illness, pregnant women, people who had been administered mood stabilisers or any
steroid or hormonal supplement (e.g. oestrogen)
Country: Israel.
Interventions 1. DHEA: dose 50 mg/day for first 2 weeks, 100 mg/day for following 2 weeks, finally
150 mg/day for last 8 weeks (each administered in divided morning and evening doses)
. N = 20
2. Placebo: N = 20.
Other concurrent treatments: participants required to have been maintained on a stable
dose of olanzapine for at least 1 month before study commencement. Participants were
required to continue taking this dose of olanzapine throughout the duration of the study.
Aside from olanzapine, concurrent medications allowed included medications that were
clinically required before study recruitment to maintain and stabilise clinical status (e.g.
benzodiazepines). Clinicians were requested to not change these ancillary medications
over the course of the study. All participants entered a 1-week, single-blind, placebo lead-
in phase of the study
Outcomes Mental state: total psychotic symptoms (PANSS), positive psychotic symptoms (PANSS)
, negative psychotic symptoms (PANSS), depression (CDSS)
Global state: leaving the study early.
Adverse events: extrapyramidal symptoms (parkinsonism) (SAS), body weight
Unable to use cognitive functioning: ’Mindstreams’ cognitive test battery (Go-NoGo
Response Inhibition Test, Stroop Interference Test, Staged Information Processing Speed
tests); test of verbal and non-verbal memory. Data not provided. Study authors reported
no significant differences in cognitive performance between intervention and control
groups
Adverse events: extrapyramidal symptoms (tardive dyskinesia, akathisia) (BARS/AIMS).
Only data for intervention groups reported (Table 1). No analyses could be undertaken.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients thenwere randomised (by
means of random number generation)...”
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Strous 2007 (Continued)
(pg 97)
Allocation concealment (selection bias) Low risk Quote (from correspondence): “Randomi-
sation numbers provided by statistician to
research assistant assigning study medica-
tion and maintained under lock and key in
concealed fashion”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participant/providers: Yes. Quote: “...to re-
ceive either DHEA or placebo, each for 12
weeks in a double-blind manner” (pg 97)
Outcome assessors blinded (source: corre-
spondence).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” - probably under-
taken.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded (source: corre-
spondence).
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk All outcome measures reported.
Other bias High risk No data given on numbers of individuals
screened for study inclusion. Tendency to-
wards baseline imbalance in SANS scores
(P value = 0.051)
AIMS - Abnormal Involuntary Movement Scale
BARS - Barnes Akathisia Rating Scale
BDI - Beck Depression Inventory
BPRS - Brief Psychaitric Rating Scale
BPRS PSS - BPRS Positive Symptom Subscale
CANTAB - Cambridge Neuropsychological Test Automated Battery
CDSS - Calgary Depression Scale for Schizophrenia
CGI-S - Clinical Global Impressions Scale
CPZ - Chlorpromazine
CVLT - California Verbal Learning Test
DHEA - Dehydroepiandrosterone
DSM - Diagnostic and Statistical Manual of Mental Disorders
ESRS - Extrapyramidal Symptom Rating Scale
F - Female
GSK - GlaxoSmithKline
HAMA Hamilton Scale for Anxiety
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HAMD - Hamilton Scale for Depression
HDRS-17 - Hamilton Depression Rating Scale - 17 item
LOCF - Last observation carried forward
M - Male
MADRS - Montgomery-Asberg Depression Rating Scale
NARSAD - National Alliance for Research on Schizophrenia and Depression
NIH - National Institutes of Health
NIMH - National Institute of Mental Health
OAS - Overt Aggression Scale
PANSS - Positive and Negative Syndrome Scale for Schizophrenia
PMD - Psychotic major depression
QOL - Quality of life
SANS - Scale for the Assessment of Negative Symptoms
SAS - Simpson-Angus Extrapyramidal Symptom Scale
SHRS - St Hans Rating Scale
UKU - Udvalg for Kliniske Undersøgelser side effects rating scale
USPHS - United States Public Health Service
YMRS - Young Mania Rating Scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barkai 1985 Allocation: not randomised (not an intervention study, review article)
Beasley 1998 Allocation: randomised.
Participants: people with psychosis.
Intervention: olanzapine vs haloperidol vs placebo, not antiglucocorticoid or related intervention
Belanoff 2002 Allocation: randomised.
Participants: people with psychotic major depression.
Intervention: dose finding study (50 mg to 400 mg of mifepristone), not a placebo-controlled trial
Brambilla 1988 Allocation: not randomised (all participantts were allocated to receive placebo treatment first, followed by the
intervention treatment)
David 1999 Allocation: randomised.
Participants: people with psychosis.
Intervention: olanzapine vs risperidone, not antiglucocorticoid or related intervention
Harrigan 2004 Allocation: randomised.
Participants: people with a psychotic disorder.
Interventions: not an intervention study (ketoconazole administered as CYP inhibitor to examine antipsychotic
effects on cardiac functioning measures)
Iager 1986 Allocation: randomised.
Participants: people with psychosis.
Intervention: 1-desamino-8-D-arginine vasopressin (DDAVP) vs placebo, not antiglucocorticoid or related in-
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(Continued)
tervention
Katz 2002 Allocation: not randomised (not an intervention study, review article)
Kim 1960 Allocation: not randomised (case control study).
Kline 1968 Allocation: not randomised.
Korsgaard 1981 Allocation: not randomised (all participantts were allocated to receive placebo treatment first, followed by the
intervention treatment)
Lane 2001 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: clozapine plus water vs clozapine plus super-strength grapefruit juice, not antiglucocorticoid or
related intervention
Lembke 2013 Allocation: not randomised (not an intervention study).
Loranger 1968 Allocation: randomised.
Participants: mixed diagnostic group (diagnoses: schizophrenic reaction (50%), psychoneurotic reaction (22%)
, manic-depressive reaction (18%), sociopathic personality disturbance (5%), involutional psychotic reaction
(3%), ’paranoid state’ (2%).
Interventions: cyclopregnol (6beta-hydroxy-3,5-cyclopregnan-20-one) vs chlorpromazine vs placebo, not antiglu-
cocorticoid or related intervention
Miodownik 2011 Allocation: randomised.
Participants: schizophrenia, schizoaffective disorder.
Intervention: L-theanine vs placebo.
Reason for exclusion: not an antiglucocorticoid treatment.
Nihalani 2007 Allocation: not randomised (not an intervention study, review article)
Rees 1951 Allocation: not randomised (case control study).
Rees 1956 Allocation: not randomised (case control study).
Rothschild 2005 Allocation: not randomised (not an intervention study, letter to the editor)
Schatzberg 2003 Allocation: not randomised (not an intervention study, review article)
Silbergeld 1973 Allocation: randomised.
Participants: people with depression, schizophrenia, anxiety-type reactions
Intervention: dexamethasone vs placebo.
Reason for exclusion: no includable data.
Simpson 2005 Allocation: not randomised (no comparison group, all participants received intervention treatment)
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(Continued)
Stein 1984 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: vasopressin derivative vs placebo, not antiglucocorticoid or related intervention
Tollefson 1998 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: olanzapine vs haloperidol, not antiglucocorticoid or related intervention
Young 2004 Allocation: randomised.
Participants: people with bipolar disorder, not psychotic disorder
CYP - Cytochrome P
mg - Milligrams
Characteristics of studies awaiting assessment [ordered by study ID]
Hardwick 1957
Methods Allocation: unclear.
Blindness: double (preliminary investigation only, ’main series’ not an RCT)
Duration: 15 days.
Funded by: British Drug Houses Ltd.
Participants Diagnosis: schizophrenia, dementia, ’anxiety hysteria’, ’anxiety state’, ’depressive state’
N = 10 (preliminary investigation) and N = 10 (main series).
Age: 28 to 76 years.
Sex (M:F): preliminary investigation 2:8; main series 3:7.
Setting: preliminary investigation: unclear; main series: outpatients
History: preliminary investigation: ’chronic’ average length of illness unclear; main series: varied, but predominantly
described as ’longstanding’; average duration of illness unclear
Excluded: unclear.
Country: United Kingdom.
Interventions Preliminary investigation: 300 mg/day 6B-hydroxy-3:5-cyclopregnan-20-one for 15 days, followed by placebo (15
days) (N unknown) or 15 days placebo, followed by 15 days 300 mg/day 6B-hydroxy-3:5-cyclopregnan-20-one (N
unknown)
Main series: 300 mg/day 6B-hydroxy-3:5-cyclopregnan-20-one.
Outcomes Unclear (participant interview and subjective report only, no standardised measures used)
Notes Awaiting assessment given lack of available information.
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Kleiser 1984
Methods Allocation: unclear.
Blindness: unclear.
Duration: unclear.
Funding: unclear.
Participants Diagnosis: schizophrenia.
Age: unclear.
Interventions 1. Unclear: dose unclear. N = unclear.
2. Unclear: dose unclear. N = unclear.
Outcomes Unclear.
Notes Awaiting assessment given lack of available information.
Owen 1996
Methods Allocation: unclear.
Blindness: unclear.
Duration: unclear.
Funding: unclear.
Participants Diagnosis: schizophrenia.
Age: unclear.
Interventions 1. Unclear: dose unclear. N = unclear.
2. Unclear: dose unclear. N = unclear.
Outcomes Unclear.
Notes Awaiting assessment given lack of available information.
Pivac 2002
Methods Allocation: unclear.
Blindness: unclear.
Duration: unclear.
Funding: unclear.
Participants Diagnosis: schizophrenia.
Age: unclear.
Interventions 1. Unclear: dose unclear. N = unclear.
2. Unclear: dose unclear. N = unclear.
Outcomes Unclear
Notes Awaiting assessment given lack of available information.
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Sluchevskii 1986
Methods Allocation: unclear.
Blindness: unclear.
Duration: unclear.
Funding: unclear.
Participants Diagnosis: alcohol abstinence syndrome, acute and chronic alcoholic psychoses; alcoholism
Age: unclear.
Gender: unclear.
Interventions 1. Vasopressin: dose unclear.
2. Corticotropin: dose unclear.
Outcomes Unclear.
Notes Awaiting assessment given lack of available information.
Smidt 1988
Methods Allocation: unclear.
Blindness: unclear.
Duration: 3 weeks.
Funding: unclear.
Participants Diagnosis: schizophrenia.
Age: 22 to 39 years.
N = 12.
Age: unclear.
Sex (M:F): unclear.
Setting: unclear.
History: unclear.
Excluded: unclear.
Interventions 1. Prednisolone: dose unclear. N = unclear.
2. Unclear: dose unclear. N = unclear.
Other concurrent treatments: neuroleptic medication.
Outcomes Unclear.
Notes Awaiting assessment given lack of available information.
Volk 1976
Methods Allocation: randomised.
Blindness: unclear.
Duration: unclear.
Funding: unclear.
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Volk 1976 (Continued)
Participants Diagnosis: unclear
N = unclear.
Age: unclear.
Sex (M:F): unclear.
Setting: unclear.
History: unclear.
Excluded: unclear.
Interventions 1. Unclear: dose unclear. N = unclear.
2. Unclear: dose unclear. N = unclear.
Outcomes Unclear.
Notes Awaiting assessment given lack of available information.
Volk 1977
Methods Allocation: unclear.
Blindness: unclear.
Duration: unclear.
Funding: unclear.
Participants Diagnosis: unclear.
N = unclear.
Age: unclear.
Sex (M:F): unclear.
Setting: unclear.
History: unclear.
Excluded: unclear.
Interventions 1. Unclear: dose unclear. N = unclear.
2. Unclear: dose unclear. N = unclear.
Outcomes Unclear.
Notes Awaiting assessment given lack of available information.
Watson 2002 (N0573099798)
Methods Allocation: unclear.
Blindness: unclear.
Duration: unclear.
Funding: unclear.
Participants Diagnosis: unclear.
N = unclear.
Age: unclear.
Sex (M:F): unclear.
65Antiglucocorticoid and related treatments for psychosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Watson 2002 (N0573099798) (Continued)
Setting: unclear.
History: unclear.
Excluded: unclear.
Interventions 1. Unclear: dose unclear. N = unclear.
2. Unclear: dose unclear. N = unclear.
Outcomes Unclear.
Notes Awaiting assessment given lack of available information.
F - Female
M - Male
RCT - Randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Jarskog 2009
Trial name or title Dehydroepiandrosterone (DHEA) for schizophrenia.
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks.
Funded by Stanley Foundation.
Participants Diagnosis: schizophrenia, schizoaffective disorder.
N = 30.
Age: unclear.
Sex (M:F): men only.
Setting: unclear.
History: persistent symptoms with prior adequate trials of antipsychotic drugs
Excluded: unclear.
Country: USA.
Interventions 1. DHEA: dose 400 mg/day.
2. Placebo.
Other concurrent treatments: unclear, DHEA administered as adjunctive treatment
Outcomes Mental state: positive and negative symptoms, psychopathology (PANSS)
Global state: CGI.
Adverse effects: AIMS.
Starting date Unclear.
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Jarskog 2009 (Continued)
Contact information Dr L Fredrik Jarskog
1. Department of Psychiatry,
University of North Carolina at Chapel Hill
CB # 7160
2. Neurosciences Hospital, Chapel Hill, NC 27599 USA
Email address: jarskog@med.unc.edu
Notes
Solvason 2008
Trial name or title Treatment of schizoaffective disorder using mifepristone.
Methods Allocation: unclear (quote: “randomised”).
Blindness: unclear (quote: “double-blind”).
Duration: unclear.
Funded by Pritzker Foundation.
Participants Diagnosis: schizoaffective disorder.
N = 30.
Age: 18 to 75 years.
Sex (M:F): mixed gender.
Setting: unclear.
History: unclear.
Excluded: Participants must be between the ages of 18 and 75 and must have no major medical problems
Country: USA.
Interventions 1. mifepristone; 2. placebo.
Outcomes Psychiatric symptomatology.
Starting date April 1998.
Contact information Dr Gregory H Cohen
MSW
Telephone: (650) 723-3305
Email address: ghcohen@stanford.edu
Notes
AIMS - Abnormal Involuntary Movement Scale
DHEA - Dehydroepiandrosterone
F - Female
M - Male
PANSS - Positive and Negative Syndrome Scale for Schizophrenia
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D A T A A N D A N A L Y S E S
Comparison 1. Any antiglucocorticoid versus placebo as sole treatment (data only for mifepristone)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1Mental state: 1. General - average
endpoint score (BPRS total
scores, higher score = poor)
1 5 Mean Difference (IV, Fixed, 95% CI) -5.20 [-17.91, 7.51]
2 Mental state: 2. Specific -
depression - average endpoint
score (HAMD total, higher
score = poor)
1 5 Mean Difference (IV, Fixed, 95% CI) 1.67 [-16.44, 19.78]
3 Global state: 1. General
- no clinically significant
improvement (< 30% reduction
BPRS)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 immediate 1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.93, 2.38]
3.2 short-term 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.38, 0.89]
4 Global state: 2a. Specific
- positive symptoms -
no clinically significant
improvement (< 50% reduction
BPRS, PSS)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 immediate 1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.85, 2.64]
4.2 short-term 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.43, 0.84]
5 Global state: 2b. Specific
- depressive symptoms -
no clinically significant
improvement (< 50% reduction
HAMD)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 immediate 1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.84, 2.84]
5.2 short-term 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.58, 1.19]
6 Global state: 3. Leaving the
study early
2 226 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.77, 2.01]
7 Adverse effects: 1. General -
overall number of events
2 226 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.77, 1.09]
8 Adverse effects: 2. Specific -
various effects
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 allergy - skin rash 1 221 Risk Ratio (M-H, Fixed, 95% CI) 3.31 [0.68, 16.06]
8.2 cardiovascular - mild
dizziness
1 442 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.33, 1.32]
8.3 central nervous system -
sedation
1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.36, 2.57]
8.4 central nervous system -
insomnia
1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.29, 2.93]
8.5 gastrointestinal -
constipation
1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.17, 1.26]
8.6 gastrointestinal - nausea 1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.89 [0.77, 4.63]
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8.7 gastrointestinal - vomiting 1 221 Risk Ratio (M-H, Fixed, 95% CI) 2.21 [0.78, 6.25]
8.8 metabolic -
hypercortisolaemia
1 10 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.15, 59.89]
8.9 pain - abdominal -
non-specific
1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [0.48, 5.71]
8.10 pain - abdominal - upper 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.02, 1.50]
8.11 pain - headache 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.50, 1.60]
8.12 pain - toothache 1 221 Risk Ratio (M-H, Fixed, 95% CI) 6.63 [0.81, 54.16]
Comparison 2. Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic treatment (data only
for DHEA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1Mental state: 1. General - average
endpoint score (PANSS total,
high score = poor)
1 40 Mean Difference (IV, Fixed, 95% CI) -1.70 [-10.78, 7.38]
2 Mental state: 2a. Specific -
positive and negative symptoms
- average endpoint score
(PANSS subscales, high score =
poor)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 negative subscale 1 40 Mean Difference (IV, Fixed, 95% CI) 0.70 [-2.63, 4.03]
2.2 positive subscale 1 40 Mean Difference (IV, Fixed, 95% CI) -1.0 [-3.20, 1.20]
3 Mental state: 2b. Specific -
negative symptoms - average
endpoint scores (SANS
negative subscale, high score =
poor, data skewed)
Other data No numeric data
4 Mental state: 2c. Specific -
depression - average endpoint
scores (CDSS total, high score
= poor, skewed data)
Other data No numeric data
5 Global state: 1. Leaving the
study early
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.25, 2.55]
6 Adverse effects: extrapyramidal
symptoms - average endpoint
scores parkinsonism (SAS total,
high scores = poor)
1 40 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.88, 0.88]
7 Adverse effects: weight gain -
average body weight endpoint
1 40 Mean Difference (IV, Fixed, 95% CI) 5.20 [-4.51, 14.91]
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Comparison 3. Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: 1a. General -
average endpoint score -
immediate (BPRS/PANSS
total, higher score = poor)
6 171 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.29, 0.32]
1.1 DHEA 3 106 Std. Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.40, 0.37]
1.2 ketoconazole 1 15 Std. Mean Difference (IV, Fixed, 95% CI) 1.15 [0.03, 2.28]
1.3 mifepristone 2 50 Std. Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.77, 0.36]
2 Mental state: 1b. General -
average endpoint score -
immediate (BPRS/PANSS
total, high score = poor, skewed
data)
Other data No numeric data
3 Mental state: 1c. General -
average endpoint score - short
term - only mifepristone (BPRS
total, higher score = poor)
1 20 Mean Difference (IV, Fixed, 95% CI) 2.10 [-2.86, 7.06]
4 Mental state: 2a. Specific -
positive symptoms - average
endpoint scores - immediate
(BPRS/PANSS positive
subscale, higher score = poor)
5 151 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.40, 0.25]
4.1 DHEA 3 106 Std. Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.32, 0.44]
4.2 ketoconazole 1 15 Std. Mean Difference (IV, Fixed, 95% CI) -0.03 [-1.05, 0.98]
4.3 mifepristone 1 30 Std. Mean Difference (IV, Fixed, 95% CI) -0.59 [-1.32, 0.14]
5 Mental state: 2b. Specific -
negative symptoms - average
endpoint scores - immediate
(PANSS negative subscale,
higher score = poor)
3 94 Mean Difference (IV, Fixed, 95% CI) 2.21 [-0.14, 4.55]
5.1 DHEA 2 79 Mean Difference (IV, Fixed, 95% CI) -0.34 [-3.29, 2.62]
5.2 ketoconazole 1 15 Mean Difference (IV, Fixed, 95% CI) 6.49 [2.65, 10.33]
6 Mental state: 2c. Specific -
negative symptoms - average
endpoint scores - immediate -
only DHEA (SANS, high score
= poor, skewed data)
Other data No numeric data
7 Mental state: 2d. Specific -
anxiety symptoms - average
endpoint scores - only DHEA
(HAMA total, higher score =
poor, skewed data)
Other data No numeric data
8 Mental state: 2e. Specific -
depression - average endpoint
scores - only mifepristone
(HAMD total, higher score =
poor)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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8.1 immediate 1 30 Mean Difference (IV, Fixed, 95% CI) -3.20 [-9.12, 2.72]
8.2 short-term 1 20 Mean Difference (IV, Fixed, 95% CI) 0.90 [-3.75, 5.55]
9 Mental state: 2f. Specific -
depression - average endpoint
scores (CDSS/HAMD total,
high score = poor, skewed data)
Other data No numeric data
9.1 DHEA Other data No numeric data
9.2 ketoconazole Other data No numeric data
9.3 mifepristone Other data No numeric data
10 Global state: 1. General
- no clinically significant
improvement - data only
for mifepristone (< 30%
improvement BPRS)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.32, 1.06]
11 Global state: 2a. Specific
- positive symptoms -
no clinically significant
improvement - data only
for mifepristone (< 50%
improvement BPRS, PSS)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.18, 0.81]
12 Global state: 2b. Specific -
depression - no clinically
significant improvement - data
only for mifepristone (< 50%
improvement HAMD)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.59, 1.22]
13 Global state: 3. Leaving the
study early
7 201 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.20, 1.52]
13.1 dexamethasone 1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 DHEA 3 117 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.13, 1.28]
13.3 ketoconazole 1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.4 mifepristone 2 50 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
14 Cognitive functioning: 1a.
Average endpoint scores,
various tasks
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 Information processing
and sustained attention (serial
addition task)
1 19 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.87, 0.87]
14.2 Spatial thinking (Benton
Line Orientation task)
1 19 Mean Difference (IV, Fixed, 95% CI) -0.10 [-1.63, 1.43]
15 Cognitive functioning: 1b.
Vigilance task - average
endpoint scores - skewed data
Other data No numeric data
15.2 Vigilance Other data No numeric data
16 General functioning: average
endpoint scores GAF/SOFAS
(low = poor)
2 54 Mean Difference (IV, Fixed, 95% CI) 1.05 [-5.55, 7.66]
16.1 DHEA 2 54 Mean Difference (IV, Fixed, 95% CI) 1.05 [-5.55, 7.66]
17 Adverse effects: 1. General -
overall number of events
8 223 Risk Ratio (M-H, Fixed, 95% CI) 2.66 [1.33, 5.32]
17.1 dexamethasone 1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 DHEA 4 139 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.38, 10.44]
17.3 ketoconazole 1 15 Risk Ratio (M-H, Fixed, 95% CI) 2.19 [0.60, 7.93]
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17.4 mifepristone 2 50 Risk Ratio (M-H, Fixed, 95% CI) 3.25 [1.27, 8.33]
18 Adverse effects: 2a. Specific
- extrapyramidal symptoms -
average endpoint scores - data
only for DHEA (SHRS total,
higher score = poor)
1 30 Std. Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.66, -0.15]
19 Adverse effects: 2b. Specific
- extrapyramidal symptoms -
average endpoint scores - data
only for DHEA (skewed data)
Other data No numeric data
19.1 extrapyramidal
symptoms (ESRS total, higher
score = poor)
Other data No numeric data
19.2 Akathisia and tardive
dyskinesia (AIMS/BARS total,
higher score = poor)
Other data No numeric data
20 Adverse effects: 2c. Specific:
various effects
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 allergy - skin rash - data
only for mifepristone
2 50 Risk Ratio (M-H, Fixed, 95% CI) 3.67 [0.64, 20.94]
20.2 anticholinergic - minor
blurred vision - data only for
DHEA
1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
20.3 cardiovascular - mild
dizziness - data only for
ketoconazole
1 15 Risk Ratio (M-H, Fixed, 95% CI) 2.19 [0.60, 7.93]
20.4 gastrointestinal - appetite
- increase - data only for
mifepristone
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
20.5 central nervous system
- fatigue - data only for
mifepristone
1 30 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.20, 19.78]
20.6 central nervous system -
irritability/agitation - data only
for mifepristone
1 30 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 96.13]
20.7 gastrointestinal - appetite
- decrease - data only for
mifepristone
1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
20.8 gastrointestinal -
constipation - data only for
DHEA
1 30 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 96.13]
20.9 gastrointestinal -
constipation - data only for
mifepristone
1 30 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 96.13]
20.10 gastrointestinal - nausea
- data only for mifepristone
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
20.11 hormonal -
dysmenorrhoea - data only for
mifepristone
1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
21 Quality of life: observer-rated
scale
1 55 Mean Difference (IV, Fixed, 95% CI) 6.20 [-1.37, 13.77]
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21.1 DHEA 1 55 Mean Difference (IV, Fixed, 95% CI) 6.20 [-1.37, 13.77]
Comparison 4. Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to combination
treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1Mental state: 1. General - average
endpoint score (BPRS total
scores, higher score = poor)
2 50 Mean Difference (IV, Fixed, 95% CI) -1.02 [-6.16, 4.12]
1.1 people with psychotic
depression
1 30 Mean Difference (IV, Fixed, 95% CI) -6.80 [-15.31, 1.71]
1.2 people with
schizophrenia/schizoaffective
disorder
1 20 Mean Difference (IV, Fixed, 95% CI) 2.30 [-4.15, 8.75]
2 Mental state: 2a. Specific -
positive symptoms - average
endpoint scores - people with
psychotic depression (BPRS
positive subscale, higher score =
poor)
1 30 Mean Difference (IV, Fixed, 95% CI) -2.60 [-5.67, 0.47]
3 Mental state: 2b. Specific -
depression - average endpoint
scores - people with psychotic
depression (HAMD total,
higher score = poor)
1 30 Mean Difference (IV, Fixed, 95% CI) -3.20 [-9.12, 2.72]
4 Global state: 1. General -
no clinically significant
improvement - people with
psychotic depression (< 30%
improvement BPRS)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.32, 1.06]
5 Global state: 2a. Specific
- positive symptoms -
no clinically significant
improvement - people with
psychotic depression (< 50%
improvement BPRS, PSS)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.18, 0.81]
6 Global state: 2b. Specific -
depression - no clinically
significant improvement
- people with psychotic
depression (< 50%
improvement HAMD)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.59, 1.22]
7 Global state: 3. Leaving the
study early
2 50 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
7.1 people with psychotic
depression
1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
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7.2 people with
schizophrenia/schizoaffective
disorder
1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Adverse events: overall number
of events
2 50 Risk Ratio (M-H, Fixed, 95% CI) 3.25 [1.27, 8.33]
8.1 people with psychotic
depression
1 30 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [1.41, 11.35]
8.2 people with
schizophrenia/schizoaffective
disorder
1 20 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 13.87]
Analysis 1.1. Comparison 1 Any antiglucocorticoid versus placebo as sole treatment (data only for
mifepristone), Outcome 1 Mental state: 1. General - average endpoint score (BPRS total scores, higher score =
poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 1 Any antiglucocorticoid versus placebo as sole treatment (data only for mifepristone)
Outcome: 1 Mental state: 1. General - average endpoint score (BPRS total scores, higher score = poor)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Belanoff 2001 2 40.5 (0.7) 3 45.7 (11.2) 100.0 % -5.20 [ -17.91, 7.51 ]
Total (95% CI) 2 3 100.0 % -5.20 [ -17.91, 7.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Any antiglucocorticoid versus placebo as sole treatment (data only for
mifepristone), Outcome 2 Mental state: 2. Specific - depression - average endpoint score (HAMD total, higher
score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 1 Any antiglucocorticoid versus placebo as sole treatment (data only for mifepristone)
Outcome: 2 Mental state: 2. Specific - depression - average endpoint score (HAMD total, higher score = poor)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Belanoff 2001 2 29 (11.31) 3 27.33 (8.02) 100.0 % 1.67 [ -16.44, 19.78 ]
Total (95% CI) 2 3 100.0 % 1.67 [ -16.44, 19.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Any antiglucocorticoid versus placebo as sole treatment (data only for
mifepristone), Outcome 3 Global state: 1. General - no clinically significant improvement (< 30% reduction
BPRS).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 1 Any antiglucocorticoid versus placebo as sole treatment (data only for mifepristone)
Outcome: 3 Global state: 1. General - no clinically significant improvement (< 30% reduction BPRS)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate
DeBattista 2006 31/105 23/116 100.0 % 1.49 [ 0.93, 2.38 ]
Subtotal (95% CI) 105 116 100.0 % 1.49 [ 0.93, 2.38 ]
Total events: 31 (Intervention), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
2 short-term
DeBattista 2006 23/105 44/116 100.0 % 0.58 [ 0.38, 0.89 ]
Subtotal (95% CI) 105 116 100.0 % 0.58 [ 0.38, 0.89 ]
Total events: 23 (Intervention), 44 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
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Analysis 1.4. Comparison 1 Any antiglucocorticoid versus placebo as sole treatment (data only for
mifepristone), Outcome 4 Global state: 2a. Specific - positive symptoms - no clinically significant improvement
(< 50% reduction BPRS, PSS).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 1 Any antiglucocorticoid versus placebo as sole treatment (data only for mifepristone)
Outcome: 4 Global state: 2a. Specific - positive symptoms - no clinically significant improvement (< 50% reduction BPRS, PSS)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate
DeBattista 2006 23/105 17/116 100.0 % 1.49 [ 0.85, 2.64 ]
Subtotal (95% CI) 105 116 100.0 % 1.49 [ 0.85, 2.64 ]
Total events: 23 (Intervention), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
2 short-term
DeBattista 2006 32/105 59/116 100.0 % 0.60 [ 0.43, 0.84 ]
Subtotal (95% CI) 105 116 100.0 % 0.60 [ 0.43, 0.84 ]
Total events: 32 (Intervention), 59 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0031)
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Analysis 1.5. Comparison 1 Any antiglucocorticoid versus placebo as sole treatment (data only for
mifepristone), Outcome 5 Global state: 2b. Specific - depressive symptoms - no clinically significant
improvement (< 50% reduction HAMD).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 1 Any antiglucocorticoid versus placebo as sole treatment (data only for mifepristone)
Outcome: 5 Global state: 2b. Specific - depressive symptoms - no clinically significant improvement (< 50% reduction HAMD)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate
DeBattista 2006 21/105 15/116 100.0 % 1.55 [ 0.84, 2.84 ]
Subtotal (95% CI) 105 116 100.0 % 1.55 [ 0.84, 2.84 ]
Total events: 21 (Intervention), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 short-term
DeBattista 2006 34/105 45/116 100.0 % 0.83 [ 0.58, 1.19 ]
Subtotal (95% CI) 105 116 100.0 % 0.83 [ 0.58, 1.19 ]
Total events: 34 (Intervention), 45 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 2.93, df = 1 (P = 0.09), I2 =66%
0.5 0.7 1 1.5 2
Favours intervention Favours control
78Antiglucocorticoid and related treatments for psychosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Any antiglucocorticoid versus placebo as sole treatment (data only for
mifepristone), Outcome 6 Global state: 3. Leaving the study early.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 1 Any antiglucocorticoid versus placebo as sole treatment (data only for mifepristone)
Outcome: 6 Global state: 3. Leaving the study early
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belanoff 2001 0/2 0/3 Not estimable
DeBattista 2006 27/105 24/116 100.0 % 1.24 [ 0.77, 2.01 ]
Total (95% CI) 107 119 100.0 % 1.24 [ 0.77, 2.01 ]
Total events: 27 (Intervention), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Any antiglucocorticoid versus placebo as sole treatment (data only for
mifepristone), Outcome 7 Adverse effects: 1. General - overall number of events.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 1 Any antiglucocorticoid versus placebo as sole treatment (data only for mifepristone)
Outcome: 7 Adverse effects: 1. General - overall number of events
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belanoff 2001 0/2 1/3 1.6 % 0.44 [ 0.03, 7.52 ]
DeBattista 2006 71/105 85/116 98.4 % 0.92 [ 0.78, 1.10 ]
Total (95% CI) 107 119 100.0 % 0.92 [ 0.77, 1.09 ]
Total events: 71 (Intervention), 86 (Control)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Any antiglucocorticoid versus placebo as sole treatment (data only for
mifepristone), Outcome 8 Adverse effects: 2. Specific - various effects.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 1 Any antiglucocorticoid versus placebo as sole treatment (data only for mifepristone)
Outcome: 8 Adverse effects: 2. Specific - various effects
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 allergy - skin rash
DeBattista 2006 6/105 2/116 100.0 % 3.31 [ 0.68, 16.06 ]
Subtotal (95% CI) 105 116 100.0 % 3.31 [ 0.68, 16.06 ]
Total events: 6 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
2 cardiovascular - mild dizziness
DeBattista 2006 6/105 10/116 50.0 % 0.66 [ 0.25, 1.76 ]
DeBattista 2006 6/105 10/116 50.0 % 0.66 [ 0.25, 1.76 ]
Subtotal (95% CI) 210 232 100.0 % 0.66 [ 0.33, 1.32 ]
Total events: 12 (Intervention), 20 (Control)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
3 central nervous system - sedation
DeBattista 2006 7/105 8/116 100.0 % 0.97 [ 0.36, 2.57 ]
Subtotal (95% CI) 105 116 100.0 % 0.97 [ 0.36, 2.57 ]
Total events: 7 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
4 central nervous system - insomnia
DeBattista 2006 5/105 6/116 100.0 % 0.92 [ 0.29, 2.93 ]
Subtotal (95% CI) 105 116 100.0 % 0.92 [ 0.29, 2.93 ]
Total events: 5 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
5 gastrointestinal - constipation
DeBattista 2006 5/105 12/116 100.0 % 0.46 [ 0.17, 1.26 ]
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 105 116 100.0 % 0.46 [ 0.17, 1.26 ]
Total events: 5 (Intervention), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
6 gastrointestinal - nausea
DeBattista 2006 12/105 7/116 100.0 % 1.89 [ 0.77, 4.63 ]
Subtotal (95% CI) 105 116 100.0 % 1.89 [ 0.77, 4.63 ]
Total events: 12 (Intervention), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
7 gastrointestinal - vomiting
DeBattista 2006 10/105 5/116 100.0 % 2.21 [ 0.78, 6.25 ]
Subtotal (95% CI) 105 116 100.0 % 2.21 [ 0.78, 6.25 ]
Total events: 10 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
8 metabolic - hypercortisolaemia
Belanoff 2001 1/5 0/5 100.0 % 3.00 [ 0.15, 59.89 ]
Subtotal (95% CI) 5 5 100.0 % 3.00 [ 0.15, 59.89 ]
Total events: 1 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
9 pain - abdominal - non-specific
DeBattista 2006 6/105 4/116 100.0 % 1.66 [ 0.48, 5.71 ]
Subtotal (95% CI) 105 116 100.0 % 1.66 [ 0.48, 5.71 ]
Total events: 6 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
10 pain - abdominal - upper
DeBattista 2006 1/105 6/116 100.0 % 0.18 [ 0.02, 1.50 ]
Subtotal (95% CI) 105 116 100.0 % 0.18 [ 0.02, 1.50 ]
Total events: 1 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
11 pain - headache
DeBattista 2006 17/105 21/116 100.0 % 0.89 [ 0.50, 1.60 ]
Subtotal (95% CI) 105 116 100.0 % 0.89 [ 0.50, 1.60 ]
Total events: 17 (Intervention), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
12 pain - toothache
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Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DeBattista 2006 6/105 1/116 100.0 % 6.63 [ 0.81, 54.16 ]
Subtotal (95% CI) 105 116 100.0 % 6.63 [ 0.81, 54.16 ]
Total events: 6 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
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Analysis 2.1. Comparison 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic
treatment (data only for DHEA), Outcome 1 Mental state: 1. General - average endpoint score (PANSS total,
high score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic treatment (data only for DHEA)
Outcome: 1 Mental state: 1. General - average endpoint score (PANSS total, high score = poor)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Strous 2007 20 52.1 (13.3) 20 53.8 (15.9) 100.0 % -1.70 [ -10.78, 7.38 ]
Total (95% CI) 20 20 100.0 % -1.70 [ -10.78, 7.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic
treatment (data only for DHEA), Outcome 2 Mental state: 2a. Specific - positive and negative symptoms -
average endpoint score (PANSS subscales, high score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic treatment (data only for DHEA)
Outcome: 2 Mental state: 2a. Specific - positive and negative symptoms - average endpoint score (PANSS subscales, high score = poor)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 negative subscale
Strous 2007 20 17 (6.2) 20 16.3 (4.4) 100.0 % 0.70 [ -2.63, 4.03 ]
Subtotal (95% CI) 20 20 100.0 % 0.70 [ -2.63, 4.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
2 positive subscale
Strous 2007 20 9.6 (2) 20 10.6 (4.6) 100.0 % -1.00 [ -3.20, 1.20 ]
Subtotal (95% CI) 20 20 100.0 % -1.00 [ -3.20, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 0.70, df = 1 (P = 0.40), I2 =0.0%
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Analysis 2.3. Comparison 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic
treatment (data only for DHEA), Outcome 3 Mental state: 2b. Specific - negative symptoms - average
endpoint scores (SANS negative subscale, high score = poor, data skewed).
Mental state: 2b. Specific - negative symptoms - average endpoint scores (SANS negative subscale, high score = poor, data
skewed)
Study Interventions Mean SD N
Strous 2007 DHEA 34.2 20.2 20
Strous 2007 Placebo 31.2 22.7 20
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Analysis 2.4. Comparison 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic
treatment (data only for DHEA), Outcome 4 Mental state: 2c. Specific - depression - average endpoint scores
(CDSS total, high score = poor, skewed data).
Mental state: 2c. Specific - depression - average endpoint scores (CDSS total, high score = poor, skewed data)
Study Intervention Mean SD N
Strous 2007 DHEA 2.0 2.7 20
Strous 2007 Placebo 3.4 4.0 20
Analysis 2.5. Comparison 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic
treatment (data only for DHEA), Outcome 5 Global state: 1. Leaving the study early.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic treatment (data only for DHEA)
Outcome: 5 Global state: 1. Leaving the study early
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Strous 2007 4/20 5/20 100.0 % 0.80 [ 0.25, 2.55 ]
Total (95% CI) 20 20 100.0 % 0.80 [ 0.25, 2.55 ]
Total events: 4 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic
treatment (data only for DHEA), Outcome 6 Adverse effects: extrapyramidal symptoms - average endpoint
scores parkinsonism (SAS total, high scores = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic treatment (data only for DHEA)
Outcome: 6 Adverse effects: extrapyramidal symptoms - average endpoint scores parkinsonism (SAS total, high scores = poor)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Strous 2007 20 10.8 (1.69) 20 10.8 (1.08) 100.0 % 0.0 [ -0.88, 0.88 ]
Total (95% CI) 20 20 100.0 % 0.0 [ -0.88, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic
treatment (data only for DHEA), Outcome 7 Adverse effects: weight gain - average body weight endpoint.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 2 Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic treatment (data only for DHEA)
Outcome: 7 Adverse effects: weight gain - average body weight endpoint
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Strous 2007 20 82 (16.4) 20 76.8 (14.9) 100.0 % 5.20 [ -4.51, 14.91 ]
Total (95% CI) 20 20 100.0 % 5.20 [ -4.51, 14.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 1 Mental state: 1a. General - average endpoint score - immediate (BPRS/PANSS total, higher score =
poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 1 Mental state: 1a. General - average endpoint score - immediate (BPRS/PANSS total, higher score = poor)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 DHEA
Ritsner 2006 29 84.2 (20.7) 26 90 (21.9) 33.3 % -0.27 [ -0.80, 0.26 ]
Ritsner 2010 13 42.8 (14.9) 11 31.5 (8.8) 13.1 % 0.87 [ 0.03, 1.72 ]
Strous 2003 15 52.4 (21.8) 12 56.9 (18.6) 16.3 % -0.21 [ -0.97, 0.55 ]
Subtotal (95% CI) 57 49 62.8 % -0.02 [ -0.40, 0.37 ]
Heterogeneity: Chi2 = 5.35, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 0.08 (P = 0.94)
2 ketoconazole
Marco 2002 8 38.38 (5.8) 7 32 (4.4) 7.5 % 1.15 [ 0.03, 2.28 ]
Subtotal (95% CI) 8 7 7.5 % 1.15 [ 0.03, 2.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.044)
3 mifepristone
Flores 2006 15 38.5 (9.6) 15 45.3 (13.8) 17.6 % -0.56 [ -1.29, 0.17 ]
Gallagher 2005 10 29.2 (7.53) 10 26.9 (7.19) 12.1 % 0.30 [ -0.58, 1.18 ]
Subtotal (95% CI) 25 25 29.7 % -0.21 [ -0.77, 0.36 ]
Heterogeneity: Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 90 81 100.0 % 0.01 [ -0.29, 0.32 ]
Heterogeneity: Chi2 = 12.08, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 4.58, df = 2 (P = 0.10), I2 =56%
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Analysis 3.2. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 2 Mental state: 1b. General - average endpoint score - immediate (BPRS/PANSS total, high score =
poor, skewed data).
Mental state: 1b. General - average endpoint score - immediate (BPRS/PANSS total, high score = poor, skewed data)
Study Intervention Mean SD N
Nachshoni 2005 DHEA 21.0 12.5 15
Nachshoni 2005 Placebo 22.2 8.3 15
Analysis 3.3. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 3 Mental state: 1c. General - average endpoint score - short term - only mifepristone (BPRS total,
higher score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 3 Mental state: 1c. General - average endpoint score - short term - only mifepristone (BPRS total, higher score = poor)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gallagher 2005 10 27.6 (4.8) 10 25.5 (6.4) 100.0 % 2.10 [ -2.86, 7.06 ]
Total (95% CI) 10 10 100.0 % 2.10 [ -2.86, 7.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 4 Mental state: 2a. Specific - positive symptoms - average endpoint scores - immediate
(BPRS/PANSS positive subscale, higher score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 4 Mental state: 2a. Specific - positive symptoms - average endpoint scores - immediate (BPRS/PANSS positive subscale, higher score = poor)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 DHEA
Ritsner 2006 29 18.9 (6) 26 19.6 (6.8) 37.1 % -0.11 [ -0.64, 0.42 ]
Ritsner 2010 13 17.3 (7.2) 11 13.7 (5) 15.4 % 0.55 [ -0.27, 1.37 ]
Strous 2003 15 1.64 (0.67) 12 1.65 (0.73) 18.1 % -0.01 [ -0.77, 0.75 ]
Subtotal (95% CI) 57 49 70.6 % 0.06 [ -0.32, 0.44 ]
Heterogeneity: Chi2 = 1.80, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
2 ketoconazole
Marco 2002 8 14.75 (3.28) 7 14.86 (2.61) 10.1 % -0.03 [ -1.05, 0.98 ]
Subtotal (95% CI) 8 7 10.1 % -0.03 [ -1.05, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
3 mifepristone
Flores 2006 15 8.9 (3.42) 15 11.5 (5.02) 19.3 % -0.59 [ -1.32, 0.14 ]
Subtotal (95% CI) 15 15 19.3 % -0.59 [ -1.32, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Total (95% CI) 80 71 100.0 % -0.07 [ -0.40, 0.25 ]
Heterogeneity: Chi2 = 4.17, df = 4 (P = 0.38); I2 =4%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 2.37, df = 2 (P = 0.31), I2 =16%
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Analysis 3.5. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 5 Mental state: 2b. Specific - negative symptoms - average endpoint scores - immediate (PANSS
negative subscale, higher score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 5 Mental state: 2b. Specific - negative symptoms - average endpoint scores - immediate (PANSS negative subscale, higher score = poor)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 DHEA
Ritsner 2006 29 23 (6.6) 26 25.5 (6.9) 42.8 % -2.50 [ -6.08, 1.08 ]
Ritsner 2010 13 24.3 (7.1) 11 20 (6) 20.0 % 4.30 [ -0.94, 9.54 ]
Subtotal (95% CI) 42 37 62.8 % -0.34 [ -3.29, 2.62 ]
Heterogeneity: Chi2 = 4.41, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.22 (P = 0.82)
2 ketoconazole
Marco 2002 8 23.63 (4.41) 7 17.14 (3.13) 37.2 % 6.49 [ 2.65, 10.33 ]
Subtotal (95% CI) 8 7 37.2 % 6.49 [ 2.65, 10.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.32 (P = 0.00091)
Total (95% CI) 50 44 100.0 % 2.21 [ -0.14, 4.55 ]
Heterogeneity: Chi2 = 12.05, df = 2 (P = 0.002); I2 =83%
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Chi2 = 7.64, df = 1 (P = 0.01), I2 =87%
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Analysis 3.6. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 6 Mental state: 2c. Specific - negative symptoms - average endpoint scores - immediate - only DHEA
(SANS, high score = poor, skewed data).
Mental state: 2c. Specific - negative symptoms - average endpoint scores - immediate - only DHEA (SANS, high score = poor,
skewed data)
Study Intervention Mean SD N
Strous 2003 DHEA 26.53 18.44 15
Strous 2003 Placebo 38.42 18.51 15
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Analysis 3.7. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 7 Mental state: 2d. Specific - anxiety symptoms - average endpoint scores - only DHEA (HAMA total,
higher score = poor, skewed data).
Mental state: 2d. Specific - anxiety symptoms - average endpoint scores - only DHEA (HAMA total, higher score = poor, skewed
data)
Study Intervention Mean SD N
Strous 2003 DHEA 2.67 2.64 15
Strous 2003 Placebo 5.42 4.93 12
Analysis 3.8. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 8 Mental state: 2e. Specific - depression - average endpoint scores - only mifepristone (HAMD total,
higher score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 8 Mental state: 2e. Specific - depression - average endpoint scores - only mifepristone (HAMD total, higher score = poor)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 immediate
Flores 2006 15 21.3 (7.14) 15 24.5 (9.27) 100.0 % -3.20 [ -9.12, 2.72 ]
Subtotal (95% CI) 15 15 100.0 % -3.20 [ -9.12, 2.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 short-term
Gallagher 2005 10 7.3 (5) 10 6.4 (5.6) 100.0 % 0.90 [ -3.75, 5.55 ]
Subtotal (95% CI) 10 10 100.0 % 0.90 [ -3.75, 5.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 1.14, df = 1 (P = 0.29), I2 =12%
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Analysis 3.9. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 9 Mental state: 2f. Specific - depression - average endpoint scores (CDSS/HAMD total, high score =
poor, skewed data).
Mental state: 2f. Specific - depression - average endpoint scores (CDSS/HAMD total, high score = poor, skewed data)
Study Intervention Mean SD N
DHEA DHEA
Strous 2003 DHEA 4.1 4.5 15
Strous 2003 Placebo 5.6 4.5 12
ketoconazole ketoconazole
Marco 2002 Ketoconazole 16.0 9.2 8
Marco 2002 Placebo 23.0 6.9 7
mifepristone mifepristone
Gallagher 2005 Mifepristone 7.6 6.4 10
Gallagher 2005 Placebo 8.7 9.7 10
Analysis 3.10. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 10 Global state: 1. General - no clinically significant improvement - data only for mifepristone (< 30%
improvement BPRS).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 10 Global state: 1. General - no clinically significant improvement - data only for mifepristone (< 30% improvement BPRS)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Flores 2006 7/15 12/15 100.0 % 0.58 [ 0.32, 1.06 ]
Total (95% CI) 15 15 100.0 % 0.58 [ 0.32, 1.06 ]
Total events: 7 (Intervention), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 11 Global state: 2a. Specific - positive symptoms - no clinically significant improvement - data only
for mifepristone (< 50% improvement BPRS, PSS).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 11 Global state: 2a. Specific - positive symptoms - no clinically significant improvement - data only for mifepristone (< 50% improvement BPRS, PSS)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Flores 2006 5/15 13/15 100.0 % 0.38 [ 0.18, 0.81 ]
Total (95% CI) 15 15 100.0 % 0.38 [ 0.18, 0.81 ]
Total events: 5 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 12 Global state: 2b. Specific - depression - no clinically significant improvement - data only for
mifepristone (< 50% improvement HAMD).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 12 Global state: 2b. Specific - depression - no clinically significant improvement - data only for mifepristone (< 50% improvement HAMD)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Flores 2006 11/15 13/15 100.0 % 0.85 [ 0.59, 1.22 ]
Total (95% CI) 15 15 100.0 % 0.85 [ 0.59, 1.22 ]
Total events: 11 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 13 Global state: 3. Leaving the study early.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 13 Global state: 3. Leaving the study early
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 dexamethasone
Newcomer 1998 0/11 0/8 Not estimable
Subtotal (95% CI) 11 8 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 DHEA
Ritsner 2006 0/29 0/26 Not estimable
Ritsner 2010 3/16 5/16 55.6 % 0.60 [ 0.17, 2.10 ]
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Strous 2003 0/15 3/15 38.9 % 0.14 [ 0.01, 2.55 ]
Subtotal (95% CI) 60 57 94.4 % 0.41 [ 0.13, 1.28 ]
Total events: 3 (Intervention), 8 (Control)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
3 ketoconazole
Marco 2002 0/8 0/7 Not estimable
Subtotal (95% CI) 8 7 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 mifepristone
Flores 2006 1/15 0/15 5.6 % 3.00 [ 0.13, 68.26 ]
Gallagher 2005 0/10 0/10 Not estimable
Subtotal (95% CI) 25 25 5.6 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 104 97 100.0 % 0.56 [ 0.20, 1.52 ]
Total events: 4 (Intervention), 8 (Control)
Heterogeneity: Chi2 = 1.99, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 1.37, df = 1 (P = 0.24), I2 =27%
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Analysis 3.14. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 14 Cognitive functioning: 1a. Average endpoint scores, various tasks.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 14 Cognitive functioning: 1a. Average endpoint scores, various tasks
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Information processing and sustained attention (serial addition task)
Newcomer 1998 11 2.1 (2) 8 2.6 (1) 100.0 % -0.50 [ -1.87, 0.87 ]
Subtotal (95% CI) 11 8 100.0 % -0.50 [ -1.87, 0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Spatial thinking (Benton Line Orientation task)
Newcomer 1998 11 1.8 (1.5) 8 1.9 (1.8) 100.0 % -0.10 [ -1.63, 1.43 ]
Subtotal (95% CI) 11 8 100.0 % -0.10 [ -1.63, 1.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 3.15. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 15 Cognitive functioning: 1b. Vigilance task - average endpoint scores - skewed data.
Cognitive functioning: 1b. Vigilance task - average endpoint scores - skewed data
Study Intervention Mean SD N
Vigilance Vigilance
Newcomer 1998 Dexamethasone 2.5 2.6 11
Newcomer 1998 Placebo 2.6 1.4 8
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Analysis 3.16. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 16 General functioning: average endpoint scores GAF/SOFAS (low = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 16 General functioning: average endpoint scores GAF/SOFAS (low = poor)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 DHEA
Nachshoni 2005 15 39 (11.9) 15 34.6 (9.8) 71.7 % 4.40 [ -3.40, 12.20 ]
Ritsner 2010 13 55.8 (16.9) 11 63.2 (14.1) 28.3 % -7.40 [ -19.80, 5.00 ]
Total (95% CI) 28 26 100.0 % 1.05 [ -5.55, 7.66 ]
Heterogeneity: Chi2 = 2.49, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours intervention Favours control
96Antiglucocorticoid and related treatments for psychosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.17. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 17 Adverse effects: 1. General - overall number of events.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 17 Adverse effects: 1. General - overall number of events
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 dexamethasone
Newcomer 1998 0/11 0/8 Not estimable
Subtotal (95% CI) 11 8 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 DHEA
Nachshoni 2005 3/15 0/15 6.1 % 7.00 [ 0.39, 124.83 ]
Ritsner 2006 0/29 0/26 Not estimable
Ritsner 2010 0/13 0/11 Not estimable
Strous 2003 0/15 1/15 18.4 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 72 67 24.6 % 2.00 [ 0.38, 10.44 ]
Total events: 3 (Intervention), 1 (Control)
Heterogeneity: Chi2 = 1.99, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.82 (P = 0.41)
3 ketoconazole
Marco 2002 5/8 2/7 26.2 % 2.19 [ 0.60, 7.93 ]
Subtotal (95% CI) 8 7 26.2 % 2.19 [ 0.60, 7.93 ]
Total events: 5 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
4 mifepristone
Flores 2006 12/15 3/15 36.9 % 4.00 [ 1.41, 11.35 ]
Gallagher 2005 1/10 1/10 12.3 % 1.00 [ 0.07, 13.87 ]
Subtotal (95% CI) 25 25 49.2 % 3.25 [ 1.27, 8.33 ]
Total events: 13 (Intervention), 4 (Control)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
Total (95% CI) 116 107 100.0 % 2.66 [ 1.33, 5.32 ]
Total events: 21 (Intervention), 7 (Control)
Heterogeneity: Chi2 = 3.34, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.77 (P = 0.0055)
Test for subgroup differences: Chi2 = 0.38, df = 2 (P = 0.83), I2 =0.0%
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Analysis 3.18. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 18 Adverse effects: 2a. Specific - extrapyramidal symptoms - average endpoint scores - data only for
DHEA (SHRS total, higher score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 18 Adverse effects: 2a. Specific - extrapyramidal symptoms - average endpoint scores - data only for DHEA (SHRS total, higher score = poor)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nachshoni 2005 15 21.5 (4.4) 15 26.5 (6.2) 100.0 % -0.90 [ -1.66, -0.15 ]
Total (95% CI) 15 15 100.0 % -0.90 [ -1.66, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 3.19. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 19 Adverse effects: 2b. Specific - extrapyramidal symptoms - average endpoint scores - data only for
DHEA (skewed data).
Adverse effects: 2b. Specific - extrapyramidal symptoms - average endpoint scores - data only for DHEA (skewed data)
Study Intervention Mean SD N
extrapyramidal symptoms (ESRS total, higher score = poor) extrapyramidal symptoms
Ritsner 2006 DHEA 4.0 6.8 29
Ritsner 2006 Placebo 5.5 8.5 26
Ritsner 2010 DHEA 2.9 4.8 13
Ritsner 2010 Placebo 1.7 4.1 11
Akathisia and tardive dyskinesia (AIMS/BARS total, higher score = poor) Akathisia and tar
Ritsner 2006 DHEA 1.1 2.8 29
Ritsner 2006 Placebo 0.8 2.3 26
Ritsner 2010 DHEA 0.23 0.6 13
Ritsner 2010 Placebo 0.18 0.4 11
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Analysis 3.20. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 20 Adverse effects: 2c. Specific: various effects.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 20 Adverse effects: 2c. Specific: various effects
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 allergy - skin rash - data only for mifepristone
Flores 2006 4/15 0/15 33.3 % 9.00 [ 0.53, 153.79 ]
Gallagher 2005 1/10 1/10 66.7 % 1.00 [ 0.07, 13.87 ]
Subtotal (95% CI) 25 25 100.0 % 3.67 [ 0.64, 20.94 ]
Total events: 5 (Intervention), 1 (Control)
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 1.46 (P = 0.14)
2 anticholinergic - minor blurred vision - data only for DHEA
Nachshoni 2005 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
3 cardiovascular - mild dizziness - data only for ketoconazole
Marco 2002 5/8 2/7 100.0 % 2.19 [ 0.60, 7.93 ]
Subtotal (95% CI) 8 7 100.0 % 2.19 [ 0.60, 7.93 ]
Total events: 5 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
4 gastrointestinal - appetite - increase - data only for mifepristone
Flores 2006 0/15 1/15 100.0 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 15 15 100.0 % 0.33 [ 0.01, 7.58 ]
Total events: 0 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
5 central nervous system - fatigue - data only for mifepristone
Flores 2006 2/15 1/15 100.0 % 2.00 [ 0.20, 19.78 ]
Subtotal (95% CI) 15 15 100.0 % 2.00 [ 0.20, 19.78 ]
Total events: 2 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
6 central nervous system - irritability/agitation - data only for mifepristone
Flores 2006 2/15 0/15 100.0 % 5.00 [ 0.26, 96.13 ]
0.01 0.1 1 10 100
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 15 15 100.0 % 5.00 [ 0.26, 96.13 ]
Total events: 2 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
7 gastrointestinal - appetite - decrease - data only for mifepristone
Flores 2006 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
8 gastrointestinal - constipation - data only for DHEA
Nachshoni 2005 2/15 0/15 100.0 % 5.00 [ 0.26, 96.13 ]
Subtotal (95% CI) 15 15 100.0 % 5.00 [ 0.26, 96.13 ]
Total events: 2 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
9 gastrointestinal - constipation - data only for mifepristone
Flores 2006 2/15 0/15 100.0 % 5.00 [ 0.26, 96.13 ]
Subtotal (95% CI) 15 15 100.0 % 5.00 [ 0.26, 96.13 ]
Total events: 2 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
10 gastrointestinal - nausea - data only for mifepristone
Flores 2006 0/15 1/15 100.0 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 15 15 100.0 % 0.33 [ 0.01, 7.58 ]
Total events: 0 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
11 hormonal - dysmenorrhoea - data only for mifepristone
Flores 2006 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 3.21. Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment,
Outcome 21 Quality of life: observer-rated scale.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment
Outcome: 21 Quality of life: observer-rated scale
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 DHEA
Ritsner 2006 29 68.5 (13.1) 26 62.3 (15.3) 100.0 % 6.20 [ -1.37, 13.77 ]
Total (95% CI) 29 26 100.0 % 6.20 [ -1.37, 13.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 4.1. Comparison 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to
combination treatment, Outcome 1 Mental state: 1. General - average endpoint score (BPRS total scores,
higher score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to combination treatment
Outcome: 1 Mental state: 1. General - average endpoint score (BPRS total scores, higher score = poor)
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 people with psychotic depression
Flores 2006 15 38.5 (9.6) 15 45.3 (13.8) 36.5 % -6.80 [ -15.31, 1.71 ]
Subtotal (95% CI) 15 15 36.5 % -6.80 [ -15.31, 1.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
2 people with schizophrenia/schizoaffective disorder
Gallagher 2005 10 29.2 (7.53) 10 26.9 (7.19) 63.5 % 2.30 [ -4.15, 8.75 ]
Subtotal (95% CI) 10 10 63.5 % 2.30 [ -4.15, 8.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 25 25 100.0 % -1.02 [ -6.16, 4.12 ]
Heterogeneity: Chi2 = 2.79, df = 1 (P = 0.09); I2 =64%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Chi2 = 2.79, df = 1 (P = 0.09), I2 =64%
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Analysis 4.2. Comparison 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to
combination treatment, Outcome 2 Mental state: 2a. Specific - positive symptoms - average endpoint scores -
people with psychotic depression (BPRS positive subscale, higher score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to combination treatment
Outcome: 2 Mental state: 2a. Specific - positive symptoms - average endpoint scores - people with psychotic depression (BPRS positive subscale, higher score = poor)
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Flores 2006 15 8.9 (3.42) 15 11.5 (5.02) 100.0 % -2.60 [ -5.67, 0.47 ]
Total (95% CI) 15 15 100.0 % -2.60 [ -5.67, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to
combination treatment, Outcome 3 Mental state: 2b. Specific - depression - average endpoint scores - people
with psychotic depression (HAMD total, higher score = poor).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to combination treatment
Outcome: 3 Mental state: 2b. Specific - depression - average endpoint scores - people with psychotic depression (HAMD total, higher score = poor)
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Flores 2006 15 21.3 (7.14) 15 24.5 (9.27) 100.0 % -3.20 [ -9.12, 2.72 ]
Total (95% CI) 15 15 100.0 % -3.20 [ -9.12, 2.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to
combination treatment, Outcome 4 Global state: 1. General - no clinically significant improvement - people
with psychotic depression (< 30% improvement BPRS).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to combination treatment
Outcome: 4 Global state: 1. General - no clinically significant improvement - people with psychotic depression (< 30% improvement BPRS)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Flores 2006 7/15 12/15 100.0 % 0.58 [ 0.32, 1.06 ]
Total (95% CI) 15 15 100.0 % 0.58 [ 0.32, 1.06 ]
Total events: 7 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to
combination treatment, Outcome 5 Global state: 2a. Specific - positive symptoms - no clinically significant
improvement - people with psychotic depression (< 50% improvement BPRS, PSS).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to combination treatment
Outcome: 5 Global state: 2a. Specific - positive symptoms - no clinically significant improvement - people with psychotic depression (< 50% improvement BPRS, PSS)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Flores 2006 5/15 13/15 100.0 % 0.38 [ 0.18, 0.81 ]
Total (95% CI) 15 15 100.0 % 0.38 [ 0.18, 0.81 ]
Total events: 5 (Experimental), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to
combination treatment, Outcome 6 Global state: 2b. Specific - depression - no clinically significant
improvement - people with psychotic depression (< 50% improvement HAMD).
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to combination treatment
Outcome: 6 Global state: 2b. Specific - depression - no clinically significant improvement - people with psychotic depression (< 50% improvement HAMD)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Flores 2006 11/15 13/15 100.0 % 0.85 [ 0.59, 1.22 ]
Total (95% CI) 15 15 100.0 % 0.85 [ 0.59, 1.22 ]
Total events: 11 (Experimental), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to
combination treatment, Outcome 7 Global state: 3. Leaving the study early.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to combination treatment
Outcome: 7 Global state: 3. Leaving the study early
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 people with psychotic depression
Flores 2006 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 people with schizophrenia/schizoaffective disorder
Gallagher 2005 0/10 0/10 Not estimable
Subtotal (95% CI) 10 10 Not estimable
Total events: 0 (Experimental), 0 (Control)
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 25 25 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to
combination treatment, Outcome 8 Adverse events: overall number of events.
Review: Antiglucocorticoid and related treatments for psychosis
Comparison: 4 Subgroup analyses - by diagnostic group: mifepristone vs placebo as adjunct to combination treatment
Outcome: 8 Adverse events: overall number of events
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 people with psychotic depression
Flores 2006 12/15 3/15 75.0 % 4.00 [ 1.41, 11.35 ]
Subtotal (95% CI) 15 15 75.0 % 4.00 [ 1.41, 11.35 ]
Total events: 12 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0092)
2 people with schizophrenia/schizoaffective disorder
Gallagher 2005 1/10 1/10 25.0 % 1.00 [ 0.07, 13.87 ]
Subtotal (95% CI) 10 10 25.0 % 1.00 [ 0.07, 13.87 ]
Total events: 1 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 25 25 100.0 % 3.25 [ 1.27, 8.33 ]
Total events: 13 (Experimental), 4 (Control)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 0.92, df = 1 (P = 0.34), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Adverse effect data for intervention group (control group not reported)
Outcome Measure Mean SD N
Akathisia BAS total 0.05 0.24 20
Tardive dyskinesia AIMS total 0.7 2.44 20
Table 2. Summary of included studies and baseline psychopathology
Study Inter-
vention
Dosage Length As
adjunct
(Y/N)
Assess-
ment
tool
BPRS/PANSS HAMD/CDSS SANS/
PANSS
negative
SANS/
PANSS
negative
Inter-
vention
Control Inter-
vention
Control Inter-
vention
Control
Be-
lanoff
2001
Mifepri-
stone
600 mg/
d
4 days N BPRS,
HAMD
51.5 (3.
5)
45.3
(11.6)
37.5
(12.0)
29.0 (5.
3)
- -
DeBat-
tista
2006
Mifepri-
stone
600 mg/
d
7 days N BPRS,
HAMD
55.8
(11.6)
55.7 (9.
2)
37.3 (8.
4)
37.3 (7.
5)
- -
Flores
2006
Mifepri-
stone
600 mg/
d
8 days Y BPRS,
HAMD
46.9 (5.
7)
50.1 (8.
5)
29.3 (5.
0)
31.5 (5.
1)
- -
Gal-
lagher
2005
Mifepri-
stone
600 mg/
d
7 days Y BPRS,
HAMD
31.5
(10.1)
27.8 (9.
7)
9.6 (8.8) 11.7 (8.
1)
- -
Nachshoni
2005
DHEA 100 mg/
d
7 days Y BPRS 23.8
(12.2)
24.9 (9.
6)
- - - -
Ritsner
2006
DHEA 200 mg/
d
6 weeks Y PANSS 91.6
(17.1)
95.6
(17.2)
- - 25.3 (6.
3)
26.7 (6.
2)
Strous
2003
DHEA Titrated
up to
100 mg/
d
6 weeks Y PANSS,
HAMD,
SANS
66.4
(20.9)
63.8
(18.8)
8.9 (5.3) 7.0 (5.6) 47.9
(13.7)
40.8
(16.5)
Strous
2007
DHEA Titrated
up to
8 weeks Y PANSS,
CDSS,
65.5
(15.6)
65.1
(18.8)
3.0 (3.7) 4.3 (3.2) 52.8
(15.9)
39.7
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Table 2. Summary of included studies and baseline psychopathology (Continued)
150 mg/
d
SANS (23.9)
Ritsner
2010
DHEA DHEA
400 mg/
d
8 weeks Y PANSS 46.2
(11.1)
37.1 (8.
8)
- - 25.8 (6.
1)
22.8 (5.
8)
Marco
2002
Keto-
conazole
Titrated
up to
800 mg/
d
4 weeks Y PANSS,
HAMD
37.5 (6.
7)
32.4 (6.
3)
20.0 (6.
0)
20.0 (5.
1)
21.6 (5.
4)
17.4 (5.
1)
New-
comer
1998
Dexam-
ethasone
Succes-
sive
doses
of 0.5, 1,
1 and 1
mg
4 days Y BPRS,
SANS
No data
reported
No data
reported
- - No data
reported
No data
reported
Table 3. Suggestions for future reviews
Title Possible included studies
Antiglucocorticoid dose for psychosis Belanoff 2002
Pregnenolone for psychosis Savitz AJ, Silverstein SM, McGovern KC, Schenkel L, Grant L. The neurosteroid, preg-
nenolone, reduces negative symptoms in patients with schizophrenia: results of a preliminary
double-blind study.Schizophrenia Bulletin. Vol 33. 2007:489-9
Marx CE, Keefe RSE, Buchanan RW, et al. Proof-of-concept trial with the neurosteroid preg-
nenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychophar-
macology. Vol 34. Issue 8. 2009:1885-903
Table 4. Suggested design for future study
Methods Allocation: randomised, clearly described.
Blinding: double, tested.
Duration: 1 week. Need short-, medium- and long-term follow-up
Participants Diagnosis: people at ultra-high risk of developing psychosis.
N = 300.*
Age: young adults.
Sex: male only (due to mifepristone interaction with progesterone receptor).
History: demonstrable HPA axis hyperactivity.
Intervention 1. Mifepristone: flexible dose 400 to 600 mg/day. N = 150.
2. Placebo. N = 150.
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Table 4. Suggested design for future study (Continued)
Outcomes Global state: relapse, time to transition to psychosis.
Service outcomes: admission, time in hospital.
Mental state: CGI, Total psychotic (BPRS) and depressive symptoms
General functioning: quality of life measures.
Neuroendocrine measurements: cortisol awakening response and circadian rhythm measured on 2 consecutive days
Notes *Powered to be able to identify a difference of ~ 20% between groups for primary outcome with
adequate degree of certainty.
Table 5. Search terms
PsycINFO (OVID 1950 to August 2009) EMBASE (OVID 1950 to August 2009) MEDLINE (OVID 1950 to August
2009)
1. Psychosis/
2. exp Acute Psychosis/
3. Affective Psychosis/
4. exp Hallucinosis/
5. exp “Paranoia (Psychosis)”/
6. exp Schizophrenia/
7. #1 or #2 or #3 or #4 or #5 or #6
8. exp Adrenal Cortex Hormones/
9. exp Glucocorticoids/
10. Corticotropin releasing factor
11. Corticotropin
12. Vasopressin
13. Hypothalamic pituitary adrenal axis
14. Corticosteroids/
15. R121919
16. ORG 34116
17. 3-acetoxyandrost-5-ene-7,17-dione
18. dehydroepiandrosterone
19. mifepristone
20. mitotane
21. aminoglutethimide
22. spironolactone
23. ketoconazole
24. metyrapone
25. #8 or #9 or #10 or #11or #12 or #13
or #14 or #15 or #16 or #17 or #18 or #19
or #20 or #21 or #22 or #23 or #24
26. #7 AND #25
27. Clinical Trials/
28. Controlled trial$.tw
29. (controlled studies or controlled study)
.tw
30. Random$.tw
1. Psychosis/ or psychotic disorder$.tw
2. exp Delusion/
3. exp Hallucination/
4. exp Paranoid Psychosis/
5. exp Schizohprenia/
6. #1 or #2 or #3 or #4 or #5
7. exp corticosteroid/
8. exp corticosteroid receptor/
9. Corticotropin releasing factor
10. Corticotropin Releasing Factor Recep-
tor
11. Corticotropin Releasing Factor Recep-
tor 1
12. Corticotropin Releasing Factor Recep-
tor 2
13. Corticotropin
14. Vasopressin
15. Hypothalamus Hypophysis Adrenal
System
16. R121919
17. ORG 34116
18. 3-acetoxyandrost-5-ene-7,17-dione
19. Prasterone
20. Mifepristone
21. Mitotane
22. Aminoglutethimide
23. Spironolactone
24. Ketoconazole
25. Metyrapone
26. # 7 or #8 or #9 or #10 or #11or #12 or
#13 or #14 or #15 or #16 or #17 or #18 or
#19 or #20 or #21 or #22 or #23 or #24 or
#25
1. exp psychotic disorders/
2. Delusions/
3. Hallucinations/
4. Paranoid Disorders/
5. Schizophrenia/
6. (psychotic disorder$ or psychoses or psy-
chosis).tw.
7. (delusion$ or hallucination$ or para-
noid$).tw.
8.
(schizoaffective disorder$ or schizophreni-
form disorder$ or schizophrenia).tw.
9. exp mood disorders/
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11. Receptors, Steroid/
12. Glucocorticoids/
13. Receptors, Corticotropin-Releasing
Hormone/
14. Receptors, Corticotropin/
15. Dexamethasone/
16. Hydrocortisone/
17. Adrenocorticotropic Hormone/
18. Corticotrophs/
19. Hydroxycorticosteroids/
20. R 121919.mp. [mp=title, original title,
abstract, name of substance word, subject
heading word]
21. ORG 34116.mp. [mp=title, original ti-
tle, abstract, name of substance word, sub-
ject heading word]
22. 3-acetoxyandrost-5-ene-7,17-dione.
mp. [mp=title, original title, abstract, name
of substance word, subject heading word]
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Table 5. Search terms (Continued)
31. Random Sampling/
32. ((singl$ or doubl$ or trebl$ or tripl$)
adj5 (blind$ or dummy or mask$)).tw
33. Placebo$mp
34. #27 or #28 or # 29 or #30 or #31 or #
32 or #32 or #33
35. #26 AND #34
27. #6 AND #26
28. exp controlled study/
29. (controlled trial$ or controlled study or
controlled studies).tw
30. random$.tw
31. single blind procedure/
32. double blind procedure/
33. ((singl$ or doubl$ or trebl$ or tripl$)
adj (blind$ or mask$ or dummy)).tw
34. placebo$.mp
35. #28 or #29 or #30 or #31 or #32 or #
33 or #34
36. #27 AND #35
23. Dehydroepiandrosterone/
24. Mifepristone/
25. Mitotane/
26. Aminoglutethimide/
27. Spironolactone/
28. Ketoconazole/
29. Metyrapone/
30. Corticotropin-Releasing Hormone/
31. 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18 or 19 or 20 or 21 or 22 or 23 or 24
or 25 or 26 or 27 or 28 or 29 or 30
31. 10 and 31
32. clinical trial.pt
33. clinical trial$.mp. [mp=title, original ti-
tle, abstract, name of substance word, sub-
ject heading word]
34. random$.mp. [mp=title, original title,
abstract, name of substance word, subject
heading word]
35. placebo.mp. [mp=title, original title,
abstract, name of substance word, subject
heading word]
36. placebo.ti,ab
37. groups.ti,ab
38. dt.mp. [mp=title, original title, ab-
stract, name of substance word, subject
heading word]
39. trial.mp. [mp=title, original title, ab-
stract, name of substance word, subject
heading word]
40. groups.mp. [mp=title, original title, ab-
stract, name of substance word, subject
heading word]
41. 32 or 33 or 34 or 35 or 36 or 37 or 38
or 39 or 40
42. 31 and 41
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A P P E N D I C E S
Appendix 1. Previous search strategies
September 2007 search
1. Cochrane Schizophrenia Group Trials Register (see Electronic searches for strategy)
2. Cochrane Central Register of Controlled Trials (CENTRAL) and bibliographic databases, including MEDLINE, PsycINFO and
EMBASE, were searched (OVID 1950 to November 2007). The search strategy used for these databases is included in an additional
table (Table 5).
3. We searched the National Research Register (http://www.updatesoftware.com/National/nrr-frame.html), Clinical Trials (http://
clincaltrials.gov/ct/gui/c/r), the Australian Clinical Trials Register (http://www.actr.org.au/trialSearch.aspx) and Current Controlled
Trials (http://www.controlled-trials.com) databases. Additionally, we searched the trial databases of pharmaceutical companies.
November 2009 search
We searched the Cochrane Schizophrenia Group Trials Register (September 2007, November 2009) using the phrase:
[(*Steroid* or *corticoid* or *cort?cotrop* or *dexamethasone* or *hydrocortisone* or *R?121919* or *ORG?34116* or *3-acetoxyan-
drost* or dehydroepiandrosteron* or *mifepristone* or *mitot?ne* or *aminoglutethimide* or *spironolactone* or *ketoconazole* or
*metyrapone* or *etomidate* or *RU-486* in TI, AB or IN fields of REFERENCE) or (*steroids* or Hydrocortisone or Corticotropin
or Mifepristone or Dehydroepiandrosterone or Etomidate or Ketoconazole or Glucocoticoid receptor antagonist or aminogluteth* or
mitotane* or dexamethas* or metyrapon* in Intervention field of STUDY)] This register is compiled by systematic searches of major
databases, hand searches and conference proceedings (see Group Module).
Appendix 2. Previously published data extraction and methods
Authors BG, SH, LP and SB independently extracted data from selected trials. When disputes arose, we attempted to resolve these by
discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data but added
the trial to the list of those awaiting assessment. We collected information on participants (age, gender, ethnicity, diagnosis, diagnostic
criteria and first-episode/prodromal criteria used, setting of care, country, inclusion and exclusion criteria for the trial, duration of treated
and untreated illness, previous treatment and psychiatric co-morbidity); interventions (description of medication, method of delivery,
dose, duration of treatment, actual dosage received) and other interventions used in intervention group; interventions in comparison
group with similar detail; outcome measures (description of measures used, timing of administration) and results (point estimates and
measures of variability, frequency counts for dichotomous variables) and methods (randomisation and allocation procedure, blinding,
number of participants randomly assigned, withdrawn, dropped out, analysed, baseline comparability, intention-to-treat analysis, other
problems).
Assessment of risk of bias in included studies
Authors BG, SH, LP and SB assessed the risk of bias of included studies using the criteria described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2009). Risk of bias was assessed as ’yes’, ’no’ or ’unclear’ on the following points.
1. Sequence generation
2. Allocation concealment
3. Blinding of participants, personnel and outcome assessors
4. Incomplete outcome data
5. Selective outcome reporting
6. Other sources of bias
All studies meeting inclusion criteria were included regardless of the outcome of the assessment of risk of bias. However, a sensitivity
analysis was performed for the primary outcome excluding trials with ’no’ or ’unclear’ ratings for allocation concealment. Poor conceal-
ment has been associated with overestimation of treatment effect (Schulz 1995). All risk of bias items were summarised and described
in the Risk of bias in included studies section.
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When disputes arose as to which category a trial should be allocated, again resolution was attempted by discussion. When this was not
possible, we did not enter the data, and we added the trial to the list of those awaiting assessment until further information could be
obtained.
Measures of treatment effect
1. Binary data
For binary outcomes, we calculated the risk ratio (RR) and its 95% confidence interval (CI) based on the fixed-effect model. Risks
ratios are more intuitive (Boissel 1999) than odds ratios, and odds ratios tend to be interpreted as risk ratios by clinicians (Deeks 2000).
This misinterpretation then leads to overestimation of the impression of the effect. When overall results were significant, we calculated
the number needed to treat for additional beneficial outcome (NNTB) and the number needed to treat for additional harmful outcome
(NNTH). When people were lost to follow-up at the end of the study, we assumed that they had had a poor outcome, and that once
they were randomly assigned, they would be included in the analysis (intention-to-treat/ITT analysis).
2. Continuous data
2.1 Rating scales
A wide range of instruments are available for measuring mental health outcomes. These instruments vary in quality; many are not valid
and are known to be subject to bias in trials of treatments for schizophrenia (Marshall 2000). Therefore, we included continuous data
from rating scales only if the measuring instrument had been described in a peer-reviewed journal.
2.2 Final endpoint value versus change data
When both final endpoint data and change data were available for the same outcome category, we presented only final endpoint data.
We acknowledge that by doing this, we may have excluded a large portion of the published change data but argue that endpoint data
are more clinically relevant, and that if change data were to be presented along with endpoint data, they would be given undeserved
equal prominence. When studies reported only change data, we contacted study authors to ask for endpoint figures.
2.3 Multiple linear regression data
Many trials in psychiatry report estimates of treatment effects from multiple linear regression models. These models adjust for varying
factors such as age, sex and baseline of the outcome. We pooled treatment estimates from these trials using fixed-effect (inverse variance)
meta-analysis. We converted P values and confidence intervals for treatment effect to standard errors and entered them into RevMan
using the generic inverse variance.
2.4 Skewed data
Continuous data on outcomes in trials relevant to mental health issues often are not normally distributed. To avoid the pitfall of
applying parametric tests to non-parametric data, we applied the following standards to continuous final value endpoint data before
inclusion: (1) Standard deviations and means were reported in the paper or could be obtained from study authors; (2) when a scale
started from zero, the standard deviation, when multiplied by two, should be less than the mean (otherwise, the mean is unlikely to
be an appropriate measure of the centre of distribution (Altman 1996)); in cases with data that are greater than the mean, we entered
data into the ’Other data’ table as skewed data. If a scale starts from a positive value (such as PANSS, which can have values from 30 to
210), the calculation described above in (2) should be modified to take the scale starting point into account. In these cases, skewness is
present if 2 SD > (S - Smin), where S is the mean score and S min is the minimum score. We reported non-normally distributed data
(skewed) in the ’Other data types’ tables.
For change data (mean change from baseline on a rating scale), it is impossible to tell whether or not data are non-normally distributed
(skewed) unless individual patient data are available. After consulting the ALLSTAT electronic statistics mailing list, we entered change
data into RevMan analyses and reported the finding in the text to summarise available information. In doing this, we assumed that
data were not skewed or that the analysis could cope with the unknown degree of skew.
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2.5 Data synthesis
For continuous outcomes, we estimated a mean difference (MD) when the same measure was used and a standardised mean difference
(SMD) when different measures were used to measure the same outcome with a fixed-effect model.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ cluster-randomisation (such as randomisation by clinician or practice), but analysis and pooling of clustered
data pose problems. First, study authors often fail to account for intraclass correlation in clustered studies, leading to a unit of analysis
error (Divine 1992) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated.
This causes type I errors (Bland 1997; Gulliford 1999). When clustering was not accounted for in primary studies, we presented the
data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we
will seek to contact first authors of studies to obtain intraclass correlation co-efficients of clustered data and will adjust for this by using
accepted methods (Gulliford 1999). When clustering has been incorporated into the analysis of primary studies, we will also present
these data as if from a non-cluster-randomised study but will adjust for the clustering effect. We have sought statistical advice and have
been advised that the binary data as presented in a report should be divided by a design effect, which is calculated by using the mean
number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1 + (m - 1) * ICC] (Donner
2002). If the ICC was not reported, it was assumed to be 0.1 (Ukoumunne 1999). If cluster studies had been appropriately analysed
with consideration of intraclass correlation co-efficients and relevant data documented in the report, we synthesised these with other
studies using the generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological, psychological) of
treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase, participants can differ
systematically from their initial state despite a wash-out phase. For the same reason, cross-over trials are not appropriate if the condition
of interest is unstable (Elbourne 2002). As both effects are very likely in psychosis, we have used only data from the first phase of cross-
over studies.
3. Studies with multiple treatment groups
When a study involved more than two treatment arms, if relevant, we presented additional treatment arms in comparisons. When
additional treatment arms were not relevant, we did not reproduce these data.
Dealing with missing data
We excluded data from studies in which more than 50% of participants in any group were lost to follow-up (this did not include
the outcome of ’leaving the study early’). In studies with less than 50% attrition, we considered people leaving early to have had the
negative outcome, except for the event of death. We analysed the impact of including studies with high attrition rates (25% to 50%)
in a sensitivity analysis. If inclusion of data from this latter group resulted in a substantive change in the estimate of effect, we did not
add the data to trials with less attrition but presented them separately.
Assessment of heterogeneity
First, we considered all included studies within any comparison to judge for clinical heterogeneity. Then we visually inspected graphs
to investigate the possibility of statistical heterogeneity. We supplemented this by using the I2 statistic, which provides an estimate of
the percentage of variability due to heterogeneity rather than to chance alone. When the I2 estimate was greater than or equal to 50%,
we interpreted this as indicating the presence of considerable levels of heterogeneity (Higgins 2003).
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Assessment of reporting biases
We assessed reporting bias by assessing whether data appropriate for use in the meta-analysis and/or results were reported for the main
clinical outcomes of the review.
Data synthesis
When appropriate, we performed meta-analysis and pooled effect estimates obtained by using the Review Manager statistical software
programme. We used a fixed-effect model. When possible, we entered data into RevMan in such a way that the area to the left of the
’line of no effect’ indicated a ’favourable’ outcome for the antiglucocorticoid interventions. Wem this was not possible, we labelled the
graphs in RevMan analyses accordingly, so that the direction of any effects was clear.
Subgroup analysis and investigation of heterogeneity
Clinical homogeneity was satisfied when participants, interventions and outcome measures were considered to be similar. When we
found heterogeneous results, we investigated the reasons for this; when heterogeneity substantially altered the results, we did not
summarise these data but presented them separately along with reasons for heterogeneity investigated by the following subgroup and
sensitivity analyses.
Subgroup analysis
• Diagnosis
• Prodrome versus first-onset versus chronic
• Type of antiglucocorticoid drug
• Adults versus adolescents
• Duration of untreated illness
Sensitivity analysis
We performed sensitivity analyses to investigate the degree to which effect sizes depend on assumptions made by review authors.
Sensitivity analysis
• Excluding trials with ’high risk’ or ’unclear risk’ for allocation concealment
• Excluding trials with ’high risk’ or ’unclear risk’ for blinding of outcome assessment
• Excluding trials with ’high risk’ or ’unclear risk’ for intention-to-treat analysis
H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 1, 2016
Date Event Description
27 October 2008 Amended Minor amendments to protocol
9 September 2008 Amended Converted to Rev Man 5 format
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Since the protocol was published, we have updated the review in keeping with new RevMan 5 formatting. Main changes have involved
identifying a primary outcome versus secondary outcomes and the approach to assessing and reporting on risk of bias in trials and in
completing ’Summary of findings’ tables. The Cochrane Schizophrenia Group has also updated its template for the Methods section,
and we have updated these sections of the text to reflect this. For previous text, see Appendix 2.
As some trials were of very short duration, we have added a new category to the grouping of outcomes. Follow-ups less than two weeks
were considered to be ’immediate-term’, and ’short-term’ follow-up was defined as two to 12 weeks post intervention.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Dehydroepiandrosterone [therapeutic use]; Dexamethasone [therapeutic use]; Glucocorticoids [∗antagonists & inhibitors]; Hypotha-
lamo-Hypophyseal System; Ketoconazole [therapeutic use]; Mifepristone [adverse effects; therapeutic use]; Pituitary-Adrenal System;
Psychotic Disorders [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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